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Abstract

REGULATION OF PAF ACETYLHYDROLASE BY OXIDIZED PHOSPHOLIPIDS
By Rachael Griffiths, BSc (Hons)
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Dr Suzanne E. Barbour
Professor, Department of Biochemistry and Molecular Biology

Platelet-activating factor acetylhydrolase (PAFAH) is elevated in atherosclerosis and may
play a role in pathogenesis of this disease. Molecular mechanisms regulating the
expression of this lipoprotein-associated PLA2 are indistinct. Mildy oxidized low density
lipoprotein (oxLDL) and monocytes (the primary source of PAFAH) are co-localized in
early atheromas. Monocytes are activated by oxidized phospholipids (oxPL) in the
oxLDL particle. We hypothesized that oxPL-activated monocytes are the source of
increased levels of PAFAH in atherosclerosis. We found that PAFAH expression is
significantly induced by OxPAPC and in particular long-chain fractions of oxPAPC in
monocytes and cytokine-differentiated DC, but not cytokine-differentiated MO.
Furthermore, spontaneously differentiated MO and DC from monocytes of nonperiodontitis and aggressive periodontitis subjects, oxPAPC induced PAFAH in DC
alone.

1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-phosphocholine
xvi

(PEIPC)

is

a

particularly bioactive component of long-chain oxPAPC fractions that binds the
prostaglandin receptor subtypes DP1 and EP2. We revealed using selective agonists and
antagonists of these receptors that DP1 and EP2 are required for the induction of PAFAH
expression. OxPAPC stimulates IL-6 release from monocytes and this cytokine is
required for oxPAPC-induced PAFAH expression. We next tested the hypothesis that
oxPAPC did not induce PAFAH in MO because a key component of the signaling
machinery was lacking. Flow cytometric and immunoblot analyses demonstrated that
MO express very low levels of IL-6 receptor in comparison to DC and monocytes. Based
on these observations, we propose that long-chain oxPL induce PAFAH expression by
binding DP1 and/or EP2 and stimulating IL-6 production. These data strongly support the
hypothesis that oxLDL-activated DC are the source of high PAFAH levels in
atherosclerosis. Platelet activating factor (PAF) is the inflammatory phospholipids for
which PAFAH is named. PAF has been shown by other investigators to induce the
expression of PAFAH. In our physiologically relevant monocytes, PAF suppresses
PAFAH transcription and expression. 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3phosphatidylcholine (POVPC) is a short-chain oxPL that signals through the PAF
receptor. Our preliminary data suggest that like PAF, POVPC suppresses PAFAH
expression in monocytes. Further investigation into the effects of the short-chain oxPL
are warranted. Our data support the hypothesies that oxPL-activated DC are the source of
high PAFAH levels in atherosclerosis.

xvii

CHAPTER 1: GENERAL INTRODUCTION

1.1 Phospholipids
Phospholipids are biological molecules composed of a hydrophobic tail group and a
hydrophilic phosphate head group. They play an essential role as membrane lipids
providing a barrier to the cell and also possess fatty acyl components that are important
cellular energy stores. These crucial components of cellular membranes were originally
identified as structural, somewhat inert molecules. However, phospholipids are now
known to be biologically active molecules that mediate a wealth of signaling events both
inside and outside the cell.

Glycerophospholipids are composed of a diacylglycerol backbone, and a polar region
comprising

a

phosphate

group

and

an

organic

group

such

as

choline.

Glycerophospholipids are named according to the fatty acids esterified to their glycerol
backbone as well as the nature of the organic head group. The glycerol backbone has
three carbons denoted as sn-1, sn-2 and sn-3. Fatty acids are esterified to carbons at the
sn-1 and sn-2 position while a phosphate and polar head group are present at sn-3. A
glycerophospholipid with a choline head group, palmitic acid at sn-1 and arachidonic
acid esterified at sn-2 is named 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine.
Phosphatidylcholine (PC) is the most abundant of the phospholipids and is predominant
in most mammalian membranes. The variation in fatty acids at sn-1 and sn-2 combined

1

with the diversity in head group moieties gives rise to hundreds of glycerophospholipids
that possess differing structural and signaling properties.
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Figure 1: Phospholipases A1, A2, C and D selectively Cleave Phospholipids. Each
phospholipase (A1, A2, C or D) possesses the ability to cleave one of the susceptible
bonds (shown in red). Taken from Molecular Cell Biology, Lodish et al., 5th Edition,
2004
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The enzymatic hydrolysis of PC at the sn-2 position results in the formation of lysophosphatidylcholine (LPC) and free fatty acids. LPC is a detergent, and interferes with
membrane integrity. It is present in minimal quantities in membranes. LPC is a proinflammatory phospholipid in vitro and elevated levels are associated with diseases such
as asthma and high levels are known to be present upon lipid particles in atherosclerosis
(Mehta et al., 1990). The free fatty acids liberated in the enzymatic degradation of
phospholipids by phospholipase A2 are signaling molecules and precursors to a variety of
additional bioactive molecules. For example, arachidonic acid is a potent signaling
molecule that exerts regulatory control over signaling enzymes such as several protein
kinase C isoforms (McPhail et al., 1984). Arachidonic acid is also a key inflammatory
intermediate in the production of the eicosanoids, which are important signaling
mediators of inflammation and immunity. The eicosanoids are the prostaglandins,
prostacyclins, leukotrienes and thromboxanes. Eicosanoids are produced by the
conversion of arachidonic acid by selective enzymes (Figure 2). For example, the
prostaglandins are produced by the action of the cyclooxygenase (COX) enzymes, either
COX-1 (constitutively active) or COX-2 (inducible). Prostaglandin synthase enzymes
may further modify the product of COX activity, prostaglandin H2 (PGH2). The outcome
of this reaction is the production of a variety of PG species including PGE2 and PGD2
(Figure 2). PGE2 and PGD2 elicit a variety of responses including vasodilation and are
implicated in the pathogenesis of diseases such as asthma and cancer (Badawi and Badr,
2003;Wenzel, 1997). The lipoxygenase pathway is mediated by 5-lipoxygenase that
catalyzes the oxidation of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (54

HPETE). Further action of 5-lipoxygenase converts 5-HPETE to leukotriene A4 (LTA4).
LTA4 is modified to yield further leukotrienes including LTC4, LTD4 and LTE4.
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Figure 2: The Generation of Eicosanoids from Arachidonic Acid. Arachidonic acid is
enzymatically modified by Lipoxygenase to HPETE and shuttled into the leukotriene
synthesis pathway. Alternatively, arachidonic acid is converted to PGH2 by COX-1 or
COX-2. PGH2 may be further modified by PGD synthase, PGE synthase and other PG
synthases to produce an array of prostaglandins such as PGD2 and PGE2. Prostacyclins
such as PGI2 are produced by the enzymatic coversion of PGH2 by prostacyclin synthase.
Finally, thromboxane synthase converts PGH2 to thromboxanes such as TXA2
6

1.2 Platelet Activating Factor
Platelet Activating Factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) is a
specific phosphatidylcholine glycerophospholipid. Its activity was confirmed and name
coined in 1974 by Benveniste (Benveniste, 1974). PAF was identified as a soluble factor
released from IgE-stimulated basophils that activated platelets confirming earlier
observations by other researchers (Henson, 1970;Siraganian and Osler, 1971). While the
majority of glycerophospholipids possess an ester bond at the sn-1 position, PAF has an
ether bond present in this position. The alcohol at the sn-1 position of PAF is usually
hexadecanol although there are other species and these have been shown to have
markedly different potencies. PAF is produced by a variety of cells including platelets,
monocytes, macrophages and neutrophils (Benveniste, 1974;Elstad et al., 1989;Lynch et
al., 1979). Multiple inflammatory stimuli induce the release of PAF including
lipopolysaccharide (LPS), IgE, histamine and ATP (Benveniste, 1974;McIntyre et al.,
1985). PAF was also the first lipid demonstrated to bind a specific receptor to exert its
biological effects. Prior to this, lipids were thought to exert their effects by interacting
directly with the plasma membrane. However the discovery of the PAF receptor signaled
the advent of the phospholipid-signaling field. It is now known that there are many
phospholipids that bind receptors to elicit responses.
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1.3 Phospholipases
The

phospholipases

are

an

extensive

family

of

enzymes

that

catabolyze

glycerophospholipids. The thirty-five known enzymes may be classified according to the
position at which they hydrolyze phospholipids, as demonstrated in Figure 1.
Phospholipase A1 (PLA1) targets the sn-1 acyl chain and PLA2 targets the sn-2 acyl chain.
PLC cleaves at the sn-3 position before the phosphate group releasing diacylglycerol and
a phosphate-containing head group. PLD cleaves at the sn-3 position after the phosphate
group releasing phosphatidic acid and an alcohol.

The PLA2 family of enzymes itself is further subdivided into a variety of enzymes that
share a common site of phospholipid hydrolysis but differ greatly in their mechanism of
action, regulation and structures. The consequence of PLA2 activity is the hydrolysis of
the sn-2 fatty acid from a phospholipid resulting in the production of lyso-phospholipid
and the release of free fatty acid. The PLA2 enzymes are grouped based upon their
functional similarities. They are divided into secreted, calcium dependent, calciumindependent and the platelet activating factor acetylhydrolases (Table I). Within these
groups there also exists a systemic numbering system (Schaloske and Dennis, 2006).
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ENZYME

MOLECULAR

CALCIUM

ACTIVE

EXPRESSION

LOCATION

REGULATION

WEIGHT

REQUIREMENT

SITE

sPLA2

14-18

mM

His-Asp

Inducible

Extracellular

Expression

cPLA2

85

uM

GLSGS

Constitutive

Cytosolic

Ca2+, PO4

(α, β, γ)

(α,β)
Ceramide-1Phosphate

iPLA2

80

None

GxSxG

Constitutive

Cytosolic

Oligomerization

PAFAH

45

None

GxSxG

Inducible

Extracellular

Expression

(secreted
isoform)

Table 1: Selected Mammalian Phospholipase A2 Subtypes
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Members of the Secretory PLA2 (sPLA2) family are, as their name suggests
extracellularly active. These small proteins range in size from 13-15kDa, possess an
active site histidine and rely upon mM levels of calcium for their catalytic activity (Burke
and Dennis, 2009). Enzymes of the sPLA2 family play key roles in mediating
inflammation, immunity and atherosclerosis (Boyanovsky and Webb, 2009). Current
research suggests that several of these enzymes, including group V and X, are proatherogenic and an inhibitor that targets Group II, V and X (Varespladib) is currently in
Phase II clinical trials for use in atherosclerosis (Fraser et al., 2009;Hanasaki et al.,
2002;Karabina et al., 2006).

Calcium-dependent, cytosolic PLA2 (cPLA2) are larger proteins, between 61-114 kDa
that possess an active site serine (Schaloske and Dennis, 2006). The cPLA2 group
requires micromolar levels of calcium for its translocation to membranes (Schaloske and
Dennis, 2006). cPLA2 selectively targets phospholipids with arachidonic acid at the sn-2
position and is well-characterized as mediating inflammation upon its activation. The
cPLA2 knockout mouse shows significant reproductive problems perhaps associated with
the crucial role of cPLA2 in releasing arachidonic acid for the production of eicosanoids
which are key to many reproductive processes (Bonventre et al., 1997).

The calcium independent phospholipase A2 (iPLA2) group is comprised of cytosolic
enzymes that do not require calcium for their activity. Parallel to the cPLA2 group, iPLA2
relies upon an active site serine for catalytic activity. The best characterized of this group
10

is Group VIA iPLA2. First identified in 1985 by Ross et al, this enzyme is important for
remodeling of membrane phospholipids during the cell cycle (Manguikian and Barbour,
2004;Ross et al., 1985). Oligomerization is required for the activity of iPLA2 and it is
known to have truncated proteins that lack the active site. These truncated proteins bind
active iPLA2 rendering it catalytically inactive (Manguikian and Barbour, 2004). While
ATP does not appear to be required for enzymatic activity, it does stabilize iPLA2 (Lio
and Dennis, 1998).

The final group of PLA2 is that of platelet activating factor acetylhydrolase (PAFAH).
The members of this family are so-named because of their ability to hydrolyze the acetyl
group at the sn-2 position of the inflammatory phospholipid platelet-activating factor
(PAF). Two of the enzymes Group VIIB and Group VIII are intracellular enzymes while
Group VIIA is secreted. Unlike other secreted members of the PLA2 family, PAFAH
Group VIIA is calcium-independent (Schaloske and Dennis, 2006). From this point on
the term PAFAH will refer solely to PAFAH Group VIIA.

1.4 Platelet Activating Factor Acetylhydrolase
PAFAH was first identified for its biological activity upon PAF. Its subsequent
purification led to intense characterization of this unique enzyme (Stafforini et al.,
1987b). This calcium-independent enzyme hydrolyzes PAF producing lyso-PAF and
acetate (Figure 4). Lyso-PAF was long considered to be an inert product however a
recent study suggests that this product of PAFAH activity is biologically active. Lyso11

PAF is revealed to play an opposing role to PAF in neutrophil and platelet activation
(Welch et al., 2009).

PAFAH hydrolyzes PAF and phospholipids with short sn-2 acyl chains. It is also able to
target short-chain diacylglycerols, triacylglycerols and acetylated alkenanols (Min et al.,
2001). Gelb’s group first suggested that PAFAH is unusual in that it accesses its substrate
from the aqueous phase (Min et al., 1999). Recent crystallization and modeling of
PAFAH has confirmed that the active site of the enzyme is able to access substrates from
the aqueous phase (Samanta and Bahnson, 2008). This is likely an important factor in the
unique substrate specificity of PAFAH. While hydrolysis diminishes when acyl chain
length is greater than 5-carbons, oxidation and fragmentation of the sn-2 residue greatly
improves the susceptibility of the phospholipid to PAFAH. Short chain oxidized
phospholipids such as 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycerol-3-phosphocholine are
efficiently hydrolyzed and oxidation of residues up to 9-carbons long can be hydrolyzed
at a rate similar to that of PAF itself (Stremler et al., 1989b;Stremler et al., 1991). The
rate of hydrolysis of PAFAH does diminish with increasing sn-1 chain length,
presumably correlated to a diminished degree of solubility (Min et al., 1999). PAFAH
does not appear to have a preference for the nature of the sn-3 polar head group (Min et
al.,

1999).
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phospholipids,

producing

PAFAH is a 45kDa enzyme that possesses a GXSXG motif typical of serine esterases and
neutral lipases (Schaloske and Dennis, 2006). The serine residue located at the center of
the motif is nucleophilic and is flanked by histidine and an acidic aspartate (Tjoelker et
al., 1995). This catalytic triad of His351-Ser273-Asp296 is susceptible to agents that modify
active site serines such as diisopropyl fluorophosphate (DFP), phenylmethylsulphonyl
fluoride (PMSF) and Pefabloc-SC (Dentan et al., 1996;Stafforini et al., 1990). The
catalytic activity of PAFAH is also susceptible to oxidative inactivation by free radicals
and cigarette smoke extract (Ambrosio et al., 1994;Miyaura et al., 1992).

PAFAH is primarily produced by monocytes and monocyte-derived cells however, it is
also secreted by platelets, neutrophils, mast cells and in differentiating megakaryocytes
(Foulks et al., 2009;Mitsios et al., 2006;Nakajima et al., 1997;Tjoelker and Stafforini,
2000). PAFAH expression increases upon monocyte differentiation into macrophages and
dendritic cells (DC). Macrophages possess high levels of PAFAH activity that are
approximately 5-fold greater to those measured in DC (Al Darmaki et al., 2003;Stafforini
et al., 1997c). Upon secretion into the plasma, PAFAH becomes associated with
lipoprotein particles (Stafforini et al., 1987a). This circulating lipoprotein-bound form of
the enzyme is identical to PAFAH but is often described as lipoprotein-associated
phospholipase A2 (Lp-PLA2) to distinguish its location. Approximately 70% of plasma
PAFAH activity is associated with LDL (Stafforini et al., 1987a). The association of
PAFAH with lipoproteins occurs after their formation and occurs with ApoE-containing
HDL- and ApoB100-containing LDL-particles (Stafforini et al., 1987a). PAFAH activity
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does not associate with other lipoproteins such as chylomicrons and Very LDL (VLDL)
suggesting that the conformation of these apolipoproteins or additional factors play a role
in the binding of PAFAH (Stafforini et al., 1987a). PAFAH activity is stably associated
with LDL and HDL at physiological pH. However, PAFAH activity associates with HDL
in more acidic conditions. Early studies on the purification of PAFAH revealed that a
carboxyl terminal portion of ApoB co-purified with PAFAH implying that the proteins
interact (Yamada et al., 1994). Further studies demonstrated that two domains within the
PAFAH primary sequence are required for the binding of PAFAH to LDL. Residues
tyrosine-205, tryptophan-115 and leucine-116 are required for the association of these
proteins (Stafforini et al., 1999). Little is known regarding the association of PAFAH
with HDL, however recent studies suggest that multiple residues in the carboxy terminal
portion of PAFAH are required (Gardner et al., 2008). The majority of residues are not
conserved between species. This is interesting given that PAFAH preferentially
associates with HDL in most animal models including murine and bovine (Gardner et al.,
2008). PAFAH also associates with Lipoprotein (a) (Lp(a)), an atherogenic subclass of
lipoprotein (Lawn et al., 1992). Lp(a) is composed of an LDL particle with the ApoB-100
covalently linked by a disulfide bridge to apolipoprotein (a) (Lawn et al., 1992). PAFAH
likely binds to apoB100 on these particles and interestingly, PAFAH activity associated
with Lp(a) may be greater than that of LDL (Blencowe et al., 1995).
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1.5 The Regulation of Platelet Activating Factor Acetylhydrolase
The PAFAH gene is mapped to chromosome 6p12-21 and is composed of 12 exons
(Stafforini et al., 1996). The PAFAH sequence is 1.5kb long and the protein encodes 441
amino acids (Tjoelker et al., 1995). The N-terminus contains a 17 residue hydrophobic
signal peptide that is predicted to target PAFAH for secretion (Tjoelker et al., 1995).
Amino acids 18 to 41 encompass a propeptide sequence that is cleaved posttranslationally (Tjoelker et al., 1995). Constitutive PAFAH expression is dependent on
Sp1 and Sp3 transcription factors and GC-boxes in the 5’ flanking regions (Wu et al.,
2003). PAFAH expression is modulated by a variety of inflammatory stimuli. For
example, PAFAH is transcriptionally activated by lipopolysaccharide (LPS) a component
of gram-negative bacteria (Wu et al., 2003). The activation of PAFAH by LPS is
coordinated through the p38 MAPK pathway by Sp1 transactivation (Wu et al., 2004).
Relative levels of Sp1 and Sp3 associated with the GC-box are similar in resting and
LPS-stimulated cells. This suggests that the transcriptional activity of Sp1 and Sp3 in
LPS-stimulated cells is induced through post-translational modification or associations
with additional transcriptional regulators. The 5’ flanking region of PAFAH also contains
11 putative signal transducer and activator of transcription (Stat) binding elements. Other
inducers of PAFAH expression include Interferon gamma (IFNγ), Tumor necrosis factor
alpha (TNFα) and PAF (Cao et al., 1998d). PAF stimulation of PAFAH transcription has
been demonstrated in human embryonic kidney (HEK) cells stably expressing the PAF
receptor (Cao et al., 1998d). However PAF suppresses PAFAH expression in human
decidual macrophages (Narahara et al., 2003). Intriguingly, PAFAH expression is
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increased dramatically upon differentiation of monocytes into macrophages through an as
yet unknown mechanism (Elstad et al., 1989).

1.6 PAFAH and Atherosclerosis
PAFAH is closely connected to atherosclerosis (Packard et al., 2000b;Tselepis and
Chapman, 2002a;Wilensky et al., 2008), however it is unknown whether it plays a
protective or damaging role in the disease. This uncertainty stems from the knowledge
that, although PAFAH degrades pro-inflammatory ox-PL, the products of this reaction,
namely lysophosphatidylcholine (LPC) and free oxidized fatty acids may also be proatherogenic (Ninio et al., 2004b). Lysophosphatidylcholine (LPC) is especially potent,
inducing smooth muscle cell proliferation and migration leading to intimal vessel
thickening, an event that is central to the pathology of atherosclerosis (Chai et al.,
1996;Kohno et al., 1998;Ross and Agius, 1992). LPC also induces adhesion and acts as a
pro-chemoattractant to monocytes and T-cells (Kume et al., 1992;Radu et al., 2004;Rong
et al., 2002).There are several examples of altered PAFAH activity and its consequences
in vivo. For example a missense mutation in the PAFAH gene at nucleotide 994 results in
transversion of Valine to Phenylalanine at amino acid 279 of the mature protein
(Stafforini et al., 1996). This mutation results in the production of catalytically inactive
PAFAH (Stafforini et al., 1996). This mutation is homozygous in approximately 4
percent of the Japanese population (Stafforini et al., 1996) and has now also been
identified in Kirghiz and Turkish populations (Balta et al., 2001). This mutation has been
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correlated with increased incidence of stroke, myocardial infarction and atherosclerotic
occlusive disease in the Japanese population (Hiramoto et al., 1997;Yamada et al.,
1998b;Yamada et al., 2000b). The V279F mutation is also associated with increased
intimal media thickness in type 2 diabetes patients (Yamamoto et al., 2003). In animal
models, PAFAH gene transfer by adenovirus reduces atherosclerosis in Apo E-/- mice
(Quarck et al., 2001a) and PAF-antagonists reduce lesion size (Subbanagounder et al.,
1999). PAFAH forced expression reduces neointimal formation and atherosclerosis in
animal models (Arakawa et al., 2005b;Quarck et al., 2001d;Turunen et al., 2005b).
PAFAH also restores trafficking of DC to the secondary lymphoid tissues of apoE-/- mice
limiting promotion of the chronic inflammatory responses associated with progression of
atherosclerosis (Angeli et al., 2004b). PAFAH protection in these instances is likely
connected to the catabolism of pro-atherogenic ox-LDLs and/or protection of lipoproteins
from oxidation (Noto et al., 2003b;Stafforini et al., 1997e;Stremler et al., 1989b;Watson
et al., 1995).

Conversely, elevated PAFAH appears to be associated with increased incidence of
coronary artery disease in European populations (Blankenberg et al., 2003a;Stafforini et
al., 1987a;Stafforini et al., 1997d). There are associations between elevated plasma
PAFAH and a variety of cardiovascular diseases such as coronary artery calcification,
myocardial infarction and ischemic stroke (Ballantyne et al., 2004a;Ballantyne et al.,
2005b;Blake et al., 2001b;Johnston et al., 2006b;Koenig et al., 2004;O'Donoghue et al.,
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2006;Packard et al., 2000b). PAFAH is detected at significantly elevated levels in the
lesions of Watanabe hyperlipidemic rabbits compared to normal aortas of control animals
(Hakkinen et al., 1999). PAFAH is also detected at elevated levels in human
atherosclerotic lesions and is directly associated with lesion severity (Hakkinen et al.,
1999). An inactivating mutation (Ala379Val) located near the Histidine of the PAFAH
catalytic triad (His351) has been linked to decreased risk of myocardial infarction
(Abuzeid et al., 2003;Ninio et al., 2004a). Products of the PAFAH reaction have been
demonstrated to be proinflammatory and may exacerbate atherogenesis (Chen,
2004a;Tselepis and Chapman, 2002a). The PAFAH inhibitor, Darapladib is currently in
Phase III clinical trials. Thus far, Darapladib has been shown to transiently decrease
circulating C-reactive protein (CRP) and interleukin-6 (IL-6) (Mohler, III et al., 2008).
Importantly, these studies reveal that inhibition of PAFAH leads to a reduction in
necrotic core progression suggesting that PAFAH may play a role in early atherosclerosis
development (Wilensky et al., 2008).
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1.7 Liproproteins
Lipoproteins are a group of macromolecules present in plasma. They are composed of a
neutral core of lipids triacylglycerol and cholesteryl esters, enclosed by a monolayer of
phospholipids and free cholesterol. Cholesterol transport is facilitated by lipoprotein
particles that carry cholesterol in either esterified or free form, to and from the liver. The
particle is associated with one or more apolipoproteins depending upon the lipoprotein
subtype (Table II). There are five types of lipoproteins; chylomicrons (CM), very low
density lipoprotein (VLDL), Low Density Lipoprotein (LDL), Intermediate Density
Lipoprotein (IDL) and High Density Lipoprotein (HDL). Perhaps the best characterized
of the lipoproteins is low-density lipoprotein (LDL), the primary carrier of cholesterol to
cells, and high density lipoprotein (HDL) that transports cholesterol from cells to the
liver. Lipoproteins synthesis may be grouped into the exogenous or endogenous
pathways. The exogenous pathway transports dietary lipids while the endogenous
pathway transports lipids of hepatic derivation.
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Lipoprotein

Chylomicron (CM)

Density

Diameter

g/ml

nm

<0.94

Apolipoproteins

75-1200

A-I, A-II, AIV,
B-48, C-I, C-II,
C-III, E

Very

Low

Density

Lipoprotein

0.94-1.006

30-80

B-100, C-I, C-II, C-

(VLDL)

III, E

Low Density Lipoprotein (LDL)

1.006-

18-25

B-100

5-12

A-I, A-II, C-I, C-II,

1.063
High Density Lipoprotein (HDL)

1.063-1.21

C-III, E

Table 2: Properties of the Lipoprotein Species
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Ingested triglycerides and cholesterol are absorbed through the intestine and packaged
into CM in the endoplasmic reticulum of intestinal enterocytes (Brown et al., 1981).
During the packaging process, CM become associated with apoB-48, a truncated version
of the apoB100 protein. ApoB48 is required for CM assembly and is crucial for structural
integrity of these lipoprotein particles. Individuals that lack apoB48 (Anderson’s disease)
do not have the ability to secrete CM from the intestine and have hypocholesterolemia
(Dannoura et al., 1999). CM synthesis also requires the transfer of triglycerides into the
nascent apoB particle, an event that is dependent upon the activity of microsomal transfer
protein (MTP) (Berriot-Varoqueaux et al., 2000). Once CM become associated with
lipoproteins apoAI and apoCII they are released from the cell by exocytosis, secreted into
the lymph and then enter the bloodstream (Brown et al., 1981). ApoC and apoE are then
transferred from HDL to CM particles. CM-associated apoCII activates the enzyme
lipoprotein lipase (LpL) on the luminal face of the endothelial cell surface. LpL liberates
free fatty acids from the CM particle that are absorbed by cells for energy. Excess surface
material (phospholipids and free cholesterol) of the depleted CM are transferred to HDL
(HAVEL, 1957). The remainder of the chylomicron remnant binds its receptor on the
liver and is internalized and degraded by lysosomes.

In the endogenous pathway, nascent VLDL is produced by the liver and, like CM
production, requires MTP. VLDL is associated with apoAI and apoB100 upon its release,
although there are no exposed binding sites for apoB100 at this stage. Nascent VLDL
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becomes a mature particle following its association with ApoC and apoE, and the
addition of phospholipids, all donated by HDL. ApoC association results in the activation
of LpL, which converts VLDL to IDL by hydrolyzing triacylglycerol and releasing, free
fatty acids. VLDL surface remnants are shuttled to the HDL pool while the remaining
IDL is further modified. Cholesterol ester transfer protein (CETP) facilitates the removal
of cholesterol esters from HDL to IDL and triacylglycerol and phospholipids from IDL to
HDL. This process results in the formation of LDL particles. This LDL particle contains
approximately 1500 molecules of cholesteryl ester, 800 molecules of phospholipid, 500
molecules of free cholesterol and a single molecule of apolipoprotein B100 (apoB100)
(Deckelbaum et al., 1977) (Figure 4). ApoB100 is a large, complex protein that is
composed to 4,536 amino acids and has a molecular mass of 550kDa (Ginsberg and
Fisher, 2009). ApoB-100 is required for structural integrity as well as receptor
recognition of LDL. Cholesterol is an essential component of cellular membranes and is a
precursor of bile acids and steroid hormones. For cells to take up cholesterol, LDL must
bind its receptor upon cell membranes. The LDL receptor (LDL-R) is a transmembrane
glycoprotein that binds apoB upon LDL. LDL-R sits in clathrin coated pits upon the cell
surface. When LDL binds its receptor, a vesicle is pinched off and is endocytosed to the
internal cell. The low pH of the lysosomal compartment results in the dissociation of
receptor and LDL. The receptor is recycled to the cell surface while the LDL is broken
down into amino acids and cholesterol. Excess cholesterol by the endocytosis of LDL or
by surplus synthesis by the cell leads to the down-regulation of LDL-R synthesis in a
tightly regulated fashion (Brown et al., 1981).
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Mutations exist in ApoB that have physiologically detectable outcomes for example in
patients with Familial defective Apolipoprotein B-100 (FDB). The critical region in
ApoB for binding to the LDL receptor is located between residues 3359-3369 and is often
referred to as “site B” (Boren et al., 2001). FDB patients possess a substitution mutation
at position 3500 that leads to the substitution of a glutamine for an arginine at residue
3500 (Boren et al., 1998). This mutation results in a conformational change in the Cterminus of ApoB that prevents correct exposure of the critical region. Ultimately this
decreases the affinity of LDL for its receptor by 95% or more. The outcome of this
mutation is severely decreased LDL uptake and therefore hypercholesterolemia (Boren et
al., 1998).

LDL species are subclassified into four different groups based upon their size, density,
charge, lipid content and apolipoprotein content (Berneis and Krauss, 2002). These
groups are denoted as LDL-I, -II, -III and –IV and range from large, buoyant LDL to
small, dense LDL (Krauss and Burke, 1982). Individuals with a prevalence of large,
buoyant, cholesterol-rich LDL are described as possessing a Pattern A profile while those
with mainly small dense LDL (usually LDL-III) are grouped as Pattern B. Some of the
characteristics that the Pattern B profile is associated with include increased plasma
triglycerides, elevated plasma apoB and reduced HDL-cholesterol (Austin et al., 1988).
Small dense LDL are rich in triglycerides, are more likely to be taken up by arterial tissue
than larger LDL and have decreased receptor uptake and increased proteoglycan binding
(Bjornheden et al., 1996;Camejo et al., 1985;La Belle and Krauss, 1990). These results
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reveal that small dense LDL are more proatherogenic than large, buoyant LDL. This is in
agreement with further observations that show small dense LDL to be more susceptible to
oxidation. PAFAH activity preferentially associates with small dense LDL (Karabina et
al., 1994;Tselepis et al., 1995).
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Figure 4: LDL Particle Composition The LDL core is primarily composed of free
cholesterol and triacylglycerol. The outer particle surface of phospholipids, cholesteryl
esters and a single protein molecule of apolipoprotein B-100 surround this. Taken from:
Lehninger Principles of Biochemistry, 3rd Edition, 2000
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1.8 High Density Lipoprotein
HDL is well characterized as the lipoprotein that carries cholesterol from peripheral
tissues to the liver (Lewis and Rader, 2005). While elevated plasma levels of LDL are
associated with an increased risk of atherosclerosis, elevated HDL is considered to be
protective. HDL is formed by the release of lipid poor apoAI from the liver and intestine
(Lewis and Rader, 2005). Cholesterol, phospholipids and apolipoproteins are transferred
to the nascent HDL by the action of LpL upon CM. Finally, the enzyme lecithin
cholesterol acyl transferase (LCAT) esterifies HDL free cholesterol leading to the
formation of mature HDL with a cholesterol ester enriched core. HDL directly removes
excess cholesterol and phospholipids from the liver and peripheral tissues by receptors
such as scavenger receptor BI (SR-BI) and ATP-binding cassette transporter A1
transporter (ABCA1). This process allows further maturation of the HDL particle.
Cholesterol ester hydrolase (CEH) is the rate-limiting enzyme that is chiefly responsible
for the removal of excess cholesterol from peripheral tissues (Ghosh and Grogan, 1989).
CEH releases free cholesterol that is then transferred to HDL where it is re-esterified by
LCAT (Rothblat et al., 2002). Cholesterol may also be transferred from HDL in an
indirect fashion by exchange with VLDL. This process is mediated by the enzyme
cholesterol esterase transfer protein (CETP) (Lewis and Rader, 2005). Cholesterol is
exchanged with triglycerides and consequently VLDL are processed to LDL particles
which are removed from the circulation upon binding the LDL-R (Lewis and Rader,
2005).
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1.9 Atherosclerosis
Cardiovascular diseases are the number one cause of death in the United States according
to statistics by the American Heart Association. In the year 2006 statistical data revealed
that eighty million Americans suffer from one or more forms of cardiovascular disease.
The World Health Organization Report on the global burden of death revealed that
cardiovascular diseases are the leading cause of death worldwide. This group of diseases
accounts for thirty two percent of female deaths and twenty seven percent of male deaths
(World Health Organization, Global Burden of Disease Report, 2004) Globally,
cardiovascular diseases are the number one cause of death and is projected to remain so.
An estimated 17.5 million people died from cardiovascular disease in 2005, representing
30 % of all global deaths. Of these deaths, 7.6 million were due to heart attacks and 5.7
million due to stroke. About 80% of these deaths occurred in low- and middle-income
countries. If current trends are allowed to continue, by 2015 an estimated 20 million
people will die from cardiovascular disease (mainly from heart attacks and strokes)
(World Health Organization, Global Burden of Disease Report, 2004). Cardiovascular
diseases include but are not restricted to aneurysm, atherosclerosis, stroke, coronary
artery disease and myocardial infarction.

The word atherosclerosis comes from the Greek: athero (meaning paste) and sclerosis
(hardness). Atherosclerosis involves the deposition of lipid, cells and other substances in
the walls of the artery; the arterial intima. Over time these deposits harden, becoming a
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plaque. While the accumulation of lipids signals the onset of atherosclerosis, the ensuing
inflammation is responsible for the outcome of the disease (Ross, 1999). There are six
clinical stages of atherosclerosis development that define the changes occurring in the
vessel wall from the development of the fatty streak to the development of the thrombus.
Atherosclerosis is the underlying cause of cardiovascular disease. The narrowing and
hardening of the artery walls during the process of atherosclerosis may result in blood
clots blocking arteries leading to heart attack or stroke.

As illustrated in Figure 5, atherosclerosis begins with the migration of LDL from the
bloodstream into the artery wall. This event occurs early in life with fatty streaks, the first
sign of lipid deposition, measured in juveniles (Katsuda et al., 1992)(Table 3) although
this by itself is not sufficient to cause adverse outcome as atherosclerosis complications
are generally not observed until subjects reach middle age. Progressive build up of LDL
results in the narrowing of the vessel wall and late onset atherosclerosis is associated with
a hardening of this deposit, which is called the plaque. Upon its transcytosis to the arterial
intima, positively charged LDL interacts with negatively charged proteoglycans of the
extracellular matrix (Camejo et al., 1985). This traps LDL in the intima and renders it
susceptible to oxidative modification. LDL modification is not attributable to any
individual agent. Proposed mediators of LDL oxidation include sPLA2, reactive oxygen
species (ROS) and exposure to cell-derived oxidants in the sub-endothelial space as LDL
traverses from the bloodstream to the intima (Bey and Cathcart, 2000;Hanasaki et al.,
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2002;Huber et al., 2002). These initial steps in oxidation may initiate a series of chainevents that further modify LDL. The oxidative modification of LDL leads to an LDL
particle that is no longer recognized by the LDL receptor. Instead, a class of receptor
called scavenger receptors that include CD36 and SR-BI is responsible for binding and
internalizing modified LDL (Goldstein et al., 1979;Henriksen et al., 1981). Patients with
non-functional LDL receptors such as those with FDB or Familial hypercholesterolemia
(FH) have a prolonged circulation of LDL. This results in a greater likelihood of LDL
transcytosing to the arterial intima, therefore an increased opportunity for LDL
modification thereby signaling the accelerated development of atherosclerosis.
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Figure 5: Summary of Events Occuring in the Arterial Intima During
Atherosclerosis. 1. Monocytes adhere to adhesion molecules on the endothelial cell
surface on the luminal face of the artery wall before chemotaxing to the arterial intima. 2.
Monocytes then differentiate into macrophages (or Dendritic cells). 3. LDL transcytoses
from the arterial intima and is rapidly oxidized to oxLDL. 4. oxLDL is recognized by
scavenger receptors (SR) upon the macrophage cell surface and phagocytosed. This
continued process leads to the formation of foam cells that contain cytoplasmic
cholesterol droplets. 5. The efflux of cholesterol is coordinated as reverse cholesterol
transport by HDL. (Taken from Molecular Cell Biology 5th Edition. Lodish et al., 2004).
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Stage

Description

Type I: Initial

Isolated foam cells, onset, first decade

Type II: Fatty Streak

Intracellular Lipid Accumulation, first decade

Type III: Intermediate

Small intracellular lipid pools and intracellular lipid
accumulation, third decade

Type IV: Atheroma

Core of extracellular lipid and intracellular lipid accumulation,
third decade

Type V: Fibroatheroma

Lipid core and fibrotic layer, fourth decade

Type VI: Complicated

Surface Defect Thrombus, fourth decade

Table 3: Stages in Atherosclerosis Development
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1.10 Immune cells and Atherosclerosis
Both lipid and protein components of the lipoprotein particle are modified. The most
important of these modifications, with respect to atherosclerosis, is the oxidation of
phospholipids, which produces an array of potent inflammatory mediators (Tsoukatos et
al., 1997). OxLDL and its constituents signal the upregulation of adhesion molecules
such as intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) upon the surface of endothelial cells lining the artery wall
(Cominacini et al., 1997). This facilitates the binding of monocytes which are then
induced to chemotax to the arterial intima where oxLDL signals monocyte differentiation
to macrophages (Frostegard et al., 1990). Macrophages express a variety of scavenger
receptors upon their cell surface that facilitate the uptake of oxLDL. While the LDL-R is
tightly regulated, scavenger receptors are not controlled in a similar fashion. This allows
the continued uptake of oxLDL by macrophages till they are heavily lipid-laden. The
excess lipid droplets within the cell give them a histologically foamy appearance, which
has led to the term “foam cells”. CD36 and SR-BI are classic examples of scavenger
receptors that are known to recognize oxLDL and promote atherosclerosis through
macrophage foam cell formation (de Villiers and Smart, 1999;Nakagawa-Toyama et al.,
2001). However, ApoE null mice lacking CD36 and SR-BI exhibited increased
atherosclerosis compared to ApoE null control mice suggesting that there are additional
receptors key to the advancement of atherosclerosis (Moore et al., 2005). OxLDL, but not
native LDL is recognized by antibodies such as anti-Phosphorylcholine IgG (anti-PC)
and anti-cardiolipin (anti-CL) (Schenkein et al., 2001;Tuominen et al., 2006). These
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antibodies bind epitopes of oxLDL and lead to the opsonization of oxLDL through the Fc
receptor. The enhanced uptake of oxLDL by macrophages and DC would potentially lead
to increased foam cell formation. While macrophages are classically associated with
atherosclerosis, accumulating evidence indicates an important role for dendritic cells
(DC) the other monocyte-derived cell (Parums, 1992;Tabas, 2000). DC are potent antigen
presenting cells that are uniquely adapted to activate naive T-cells (Johnston et al.,
2006b). DC are present in atherosclerotic lesions and are also rich sources of
inflammatory cytokines that promote chronic inflammation in atherosclerosis (Bobryshev
et al., 2001;Bobryshev, 2005;de Kleijn and Pasterkamp, 2003;Lord and Bobryshev,
1999;Ozmen et al., 2002). oxLDL promotes DC maturation and exacerbates
atherosclerosis (Alderman et al., 2002;Coutant et al., 2004;Perrin-Cocon et al., 2001).
Additionally, DC are highly phagocytic and have been demonstrated to take up oxLDL
and become foam cells (Bobryshev, 2006).
Other immune cells that have been linked to atherosclerosis include mast cells, Tlymphocytes and B-lymphocytes. Mast cells are bone-marrow derived cells that reside in
tissues. Mast cells are found in arteries throughout atherosclerosis development,
especially in rupture-prone shoulder regions (Jeziorska et al., 1997;Kaartinen et al.,
1994). Activated mast cells release a host of inflammatory mediators including proteases
and cytokines. The mast-cell derived proteases chymase and tryptase can influence the
atheroma by degrading components of the extracellular matrix (Johnson et al., 1998) as
well as apolipoprotein B100 (Kokkonen et al., 1986). Additionally, activated mast cells
release the cytokines IL-8 and MCP-1. Both are chemokines that promote the recruitment
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of monocytes to the atheroma highlighting the potential for mast cells in atherosclerosis
development (Gerszten et al., 1999). Furthermore, mast cells express the chemokine
receptors CXCR2 (IL-8) and CCR5 (RANTES, MIP1α and MIP1β) (Gurish and Austen,
2001). These cytokines are all produced in atherosclerosis by other immune cells and are
potentially important for the homing of mast cells to the atheroma.

T-lymphocytes are cells of the adaptive immune response. T-lymphocytes (T-cells)
possess the T-cell receptor (TCR) that binds antigens. Activated T-cells are present in
human atherosclerotic plaques at sites of fibrous cap (Jonasson et al., 1986). ApoE null
mice crossed with the immunodeficient SCID model mouse have significantly reduced
atherosclerosis compared to ApoE null mice (Zhou et al., 2000). The adoptive transfer of
CD4+ T cells to ApoE null mice leads to elevated atherosclerosis (Zhou et al., 2000). Blymphocytes (B-cells) develop in the bone marrow and are antibody-producing cells.
Antibodies that recognize oxLDL are found in humans and mice (Palinski and Witztum,
2000;Wu and Lefvert, 1995). Knockout of B-cells leads to increased atherosclerosis in
LDL-R null mice (Major et al., 2002). ApoE null mice with substantial atherosclerotic
lesions have significantly increased costimulatory molecule expression compared to agematched controls (Afek et al., 2004). Activated B-cells express CD-80, a molecule that is
required for co-stimulation of T-cells. Circulating B-cells expressing CD-80 are observed
in atherosclerosis and correlate with disease severity (Tanigawa et al., 2003). Altogether
these data suggest roles for both B-cells and T-cells in atherosclerosis development.
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1.11 Animal Models of Atherosclerosis
Apolipoprotein E null mice are the classic atherosclerosis animal model. Mice do not
normally develop atherosclerosis; however the targeted deletion of apoE, a rare mutation
in the human population, leads to the retention of lipoproteins in the circulation.
Homozygous deletion of apoE in mice results in elevated LDL and VLDL (Roselaar et
al., 1996). Mice develop severe hypercholesterolemia and atherosclerosis and this process
is greatly accelerated by the switching from a regular chow diet to a lipid-rich, Western
diet (Nakashima et al., 1994). ApoE is required for receptor binding and is present
predominantly in HDL. HDL is the primary circulating lipoprotein in mice. This mouse
model is not ideal. There are stark differences in cholesterol metabolism as well as in the
lipid profile of the animals versus humans. ApoE null mice have high plasma cholesterol
however the majority of this is confined to VLDL instead of LDL, as it is in humans
(Roselaar et al., 1996). ApoE null mice contain oxidation-specific epitopes in both
plasma and in atherosclerotic lesions in macrophage-rich regions and later, in necrotic
regions that are recognized by anti-PC and anti-CL antibodies (Palinski and Witztum,
2000).

Human subjects with defects in LDL uptake such as patients with familial defective
apolipoprotein B-100 (FDB) have hypercholesterolemia that renders them susceptible to
premature atherosclerosis (Alonso et al., 2008;Boren et al., 2001). LDL-R knockout mice
were designed as an animal model of hypercholesterolemia (Ishibashi et al., 1993).
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LDL-R knockout mice maintained on a chow diet have elevated plasma cholesterol and
slowly develop atherosclerosis though the implementation of a lipid-rich diet that
accelerates the disease. At one month, the lesion morphology of LDL-R null mice is
similar to that of the apoE null mouse (Roselaar et al., 1996). The LDL-R model has
more modest lipoprotein abnormalities than the apoE model and do not develop
atherosclerosis on a regular chow diet (Ishibashi et al., 1993). The ApoE and LDL-R
knockout mice were crossed to breed a double knockout animal (Ishibashi et al., 1994).
The first study did not report that these animals had a greater propensity to develop
atherosclerosis than apoE null mice. However, a more recent study reported that the
animals displayed a modestly increased propensity of atherosclerosis development
(Witting et al., 1999).

1.12 Oxidized Phospholipids
LDL oxidation leads to the production of many lipid species. 1-palmitoyl-2arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) is an abundant phospholipid
present upon the LDL particle (Podrez et al., 2002b). While PAPC is just one example of
an LDL-associated phospholipid that is susceptible to oxidation, its relative abundance
has led to its use as a “model” lipid in the field of oxPL-signaling. Oxidized PAPC
(oxPAPC) is measured in minimally modified LDL as well as in atherosclerotic lesions
and in additional sites of chronic inflammation (Watson et al., 1997c). oxPAPC is
produced from PAPC in vitro for signaling studies. This method involves the air
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oxidation of PAPC for 24-48 hours (Watson et al., 1997c). OxPAPC comprises numerous
bioactive lipid mediators notably the short-chain lipids 1-palmitoyl-2-(5-oxovaleroyl)-snglycero-3-phosphatidylcholine

(POVPC)

and

1-palmitoyl-2-glutaroyl-sn-glycero-3-

phosphatidylcholine (PGPC) as well as long chain lipids such as epoxy-isoprostanephosphatidylcholine (PEIPC) (Leitinger, 2003) (Figure 6). OxPAPC and its constituents
have been shown to mediate many pro-atherogenic events including adhesion,
chemotaxis and differentiation of monocytes (Frostegard et al., 1997b). For example,
oxPAPC induces the chemokines monocyte-chemoattractant protein-1 (MCP1) and
interleukin-8 (IL-8) in endothelial cells (Lee et al., 2000;Yeh et al., 2001). Topical
application of oxPAPC to murine carotid arteries leads to a robust induction of the
inflammatory cytokine interleukin 6 (IL-6) (Furnkranz et al., 2005c). oxPAPC-induced
expression patterns in IL-6 null mice are mimicked by IL6 (Van Lenten et al., 2001c).
These data indicate oxPL as critical regulators of genes associated with atherosclerosis.
Oxidized phospholipids may be grouped according to the length of their sn-2 acyl chain
into short- or long-chain lipids. Figure 7 illustrates a representative mass spectra for
oxPAPC where each peak indicates an individual oxPL species. Short-chain oxidized
phospholipids such as PGPC and POVPC are more likely targets for PAFAH given their
short sn-2 acyl chain (Stremler et al., 1991). However, recent data have revealed that
long-chain oxidized phospholipids like PEIPC are also hydrolyzed by PAFAH though
less efficiently (Davis et al., 2008). Recent efforts have focused upon determination of
the specific effects of oxPAPC components and the receptors they signal through. This
has, in part been fueled by the findings that the mice lacking CD36 and SR-BI exhibited
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increased atherosclerosis (Moore et al., 2005). CD36 and SR-BI are classic scavenger
receptors that bind and internalize oxLDL and promote atherosclerosis through
macrophage foam cell formation. This illuminating discovery has allowed focus to veer
towards the investigation of other receptors and the lipids that signal through them.

39

Figure 6: Oxidized Phospholipids Present in oxPAPC and Mildly Oxidized LDL.
Oxidation of LDL generates a variety of oxidized and fragmented phospholipids, the best
studied of which are 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphatidylcholine
(POVPC), 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC) and epoxyisoprostane- phosphatidylcholine; 5,6-PEIPC (PEIPC). The structures of these oxidized
phospholipids are similar and differ only in the moiety present at the sn-2 acyl chain.
From (Leitinger, 2003).
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PGPC
POVPC

PEIPC

Figure 7: Mass Spectrometric Output of oxPAPC. Data are represented as m/z ratio
versus Relative Intensity (%). Peaks are indicated for POVPC at 594.3, PGPC at 610.2
and PEIPC at 828.6. Modified from (Watson et al., 1997a).
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1.13 Short-Chain Oxidized Phospholipids
PAF signals through a G-protein coupled receptor (PAF-R). PAF is associated with
atherosclerosis but there is also evidence to suggest oxLDL signals through the PAF-R.
oxLDL contains PAF-like lipids (Marathe et al., 2001). oxLDL stimulates activation of
the PAF-R in monocytes and down-regulation of LPS-induced PAF-R expression in
monocyte-derived macrophages (Beaudeux et al., 2004b;Hourton et al., 2001). The
oxLDL constituent POVPC has been shown to signal through the PAF-R (Pegorier et al.,
2005). Lehr et al showed that administration of oxLDL in vivo, promoted leukocyte
adhesion to endothelium and this was inhibited by the PAF-R antagonist WEB2170 (Lehr
et al., 1993b). This is consistent with reports of the in vitro and in vivo inhibition of
POVPC by WEB2170 and other PAF receptors. In the latter studies, LDL-R knockout
mice on a Western diet were administered WEB2170 for 5 weeks showed significantly
reduced fatty streak formation than control animals (Subbanagounder et al., 1999).
POVPC induces monocyte binding to endothelial cells in vitro while the structurally
similar PGPC induces adhesion of both monocyte and neutrophils (Leitinger et al., 1999).
Furthermore, POVPC inhibits LPS-induced neutrophil adhesion to endothelial cells by
down-regulating NF-kB-dependent transcription (Leitinger et al., 1999). Elevated
concentrations of POVPC and PGPC (10uM or greater) initiate apoptosis by activating
acid sphingomyelinase (Fruhwirth et al., 2006;Loidl et al., 2003). POVPC and oxPAPC
also activate Akt and c-Src in endothelial cells leading to the uncoupling of eNOS. This
results in the activation of the transcription factor sterol regulatory element binding
protein (SREBP). Upon activation, SREBP binds a sterol-responsive element (SRE) in
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the IL-8 promoter thereby increasing IL-8 transcription and thus protein (Gharavi et al.,
2006). Sphingomyelinase is the enzyme that converts sphingomyelin to ceramide, a
potent inducer of apoptosis. Apoptotic effects of oxLDL are mimicked by ceramide in
vascular smooth muscle cells (Loidl et al., 2004). In contrast to the apoptotic abilities of
high-doses of short-chain oxidized phospholipids, proliferative effects are observed at
lower concentrations. POVPC has been demonstrated to induce smooth muscle cell
proliferation (Chatterjee et al., 2004) and vascular smooth muscle cell migration and
collagen expression (Cherepanova et al., 2009).

1.14 Long-Chain Oxidized Phospholipids
Of the long-chain components that comprise oxPAPC, PEIPC is the best characterized.
PEIPC binds the toll-like receptor 4 (TLR4) as well as TLR2 or components of these
pattern recognition receptors (Erridge et al., 2008;Miller et al., 2003;Miller et al.,
2005;Walton et al., 2003b). The most recent research indicates that PEIPC binds CD14,
LPS-Binding Protein (LBP) and MD-2 to impede LPS-signaling (Erridge et al., 2008).
The potential for TLR4 signaling is interesting given that PEIPC interferes with signaling
of the classic TLR4 ligand, lipopolysaccharide (LPS) (Bluml et al., 2005c;Bochkov et al.,
2002). Additionally, oxPAPC inhibits IL-8 production stimulated by the TLR2 ligand
Pam3CSK4 oxPAPC suppresses signaling through TLR2 (Erridge et al., 2008). More
recently, PEIPC was shown to bind the prostaglandin receptor subtypes EP2 and DP1 (Li
et al., 2006d). The native ligands for these receptors are prostaglandin E2 (EP2) and
prostaglandin D2 (DP1). Binding of PEIPC to EP2 initiates monocyte adhesion to
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endothelial cells (Li et al., 2006c)). EP2 activation by PEIPC induces cyclic AMP
mimicking the signaling effects of the selective EP2 agonist Butaprost upon this Gscoupled receptor (Li et al., 2006b). Interestingly, PEIPC does not bind the three other EP
subtypes (EP1, EP3, or EP4) (Li et al., 2006e).

PEIPC, POVPC and PGPC induce monocyte binding to human aortic endothelial cells in
vitro (Subbanagounder et al., 1999). Pre-incubation of endothelial cells with the PAFreceptor antagonist WEB-2086 inhibited PEIPC- and POVPC- but not PGPC-induced
(Subbanagounder et al., 1999). Intriguingly, the investigators demonstrated that the PAFreceptor was not involved in adhesion as the PAF-receptor was not detected upon
endothelial cells and PAF itself could not reproduce the effects of the oxPL
(Subbanagounder et al., 1999). Later studies by the same group demonstrated that
POVPC and PEIPC induce a cAMP/R-Ras/ Phosphatidylinositol 3-kinase pathway to
stimulate adhesion (Cole et al., 2003). In addition to these effects upon endothelial cells,
PEIPC alone is capable of inducing IL-8 through the activation of c-src tyrosine kinase
and signal transducers and activators of transcription 3 (Stat3) (Yeh et al., 2004).
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Oxidized fatty acids and cholesterol
OxPL are not the sole bioactive components of oxLDL that play a role in atherosclerosis.
Oxidized fatty acids are believed to play a role in atherosclerosis development. 13hydroxyoctadecadienoic acid (13-HODE), produced by the non-enyzmatic oxidation of
linoleic acid regulates gene expression by binding to the peroxisome proliferatoractivated receptors (PPAR) (Corton et al., 2002;Escher and Wahli, 2000). 15-HETE is a
major product in the action of 15-lipoxygenase upon arachidonic acid. 15-HETE and 13HODE increase expression of CD36 by activation of PPARγ (Limor et al., 2008). 15HETE and 13-HODE additionally induce monocyte adhesion to endothelial cells
(Wittwer and Hersberger, 2007). 15-HETE and 13-HODE also possess anti-inflammatory
properties. For example, 15-HETE inhibits production of superoxide and suppresses the
migration of neutrophils (Takata et al., 1994). Activation of PPARa and PPARg by 13HODE and 15-HETE reduces matrix metalloproteinase-9 (MMP-9) expression (Shu et
al., 2000) (Marx et al., 1998). MMP-9 degrades the extracellular matrix, an event that
contributes to the formation of the atheroma. Oxysterols are oxygenated cholesterol
derivatives that regulate gene expression through liver X receptors (Edwards et al., 2002).
Oxysterols are present in the atheroma and are proposed to play a part in the development
of atherosclerosis. 27-hydroxycholesterol and 25-hydroxycholesterol are predominant
oxysterols in the atheroma that are well studied. 25-OH induces the release of CCR7
from murine macrophages and IL-8 in Caco-2 cells (Bai et al., 2005). 25-OH signals
through Insig proteins and block SREBP activity but activates LXR (Radhakrishnan et
al., 2007) (Edwards et al., 2002).
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1.16 Periodontitis
Periodontitis is a collective of oral inflammatory diseases. Disease onset is initiated by
infection by an oral pathogen. Severity of the disease differs and these inflammatory
diseases are generally characterized by the severe nature and localization of the affected
area. Gingivitis can lead to periodontitis. Periodontal disease is caused by a group of
predominantly gram-negative bacteria that gain access to the gingival tissue causing an
inflammatory response, the continuation of which leads to the destruction of the
periodontal ligament and the alveolar bone. Aggressive periodontitis (AgP) begins to
develop in adolescents or in young adults onwards (Oh et al., 2002). This form of
periodontitis is characterized by rapid loss of periodontal tissues (Oh et al., 2002) and is
subdivided into localized AgP (LAgP) or generalized LAgP (GAgP). Severe destruction
of periodontal tissues occurs in both diseases but occurs primarily around the incisors and
primary molars in LAgP and in the other teeth in GAgP subjects (Oh et al., 2002).
Chronic periodontitis (CP) patients are older and have slow progression of tissue loss.

Aggressive Periodontitis is a multi-factorial disease. Bacteria such as Porphyromonas
gingivalis and Aggregatibacter actinomycetemcomitans are the main etiologic factors for
the initiation of the disease. The susceptibility of individuals to periodontitis varies
greatly and appears to depend on a variety of risk factors. For example, age, race, gender
and socioeconomic status are all associated background factors or determinants for AgP.
Prevalence and severity of AgP increases with age although this is likely a result of the
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cumulative tissue destruction that occurs over time. Individuals with African or Mexican
heritage have a greater risk of periodontitis compared to Caucasians (Loe and Brown,
1991). Socioeconomic status is also a factor although this may be caused by poor oral
hygiene and other associated factors in those of lower socioeconomic status. Infection
with other diseases has also been proposed as a risk factor. For example, patients with
active infections of herpes simplex virus and Epstein-Barr virus have been associated
with AgP (Imbronito et al., 2008;Saygun et al., 2004). Smoking is classically associated
with periodontitis. GAgP and CP patients who smoke have significantly greater
attachment loss at affected areas than non-smoking counterparts (Schenkein et al., 1995).
Both forms of AgP appear to be inherited and can be found in the same families (Butler,
1969;Page et al., 1985).

Patients with GAgP, LAgP and CP have elevated levels of the pro-inflammatory
phospholipid PAF present in their gingival crevicular fluid (Emingil et al., 2000). This
has been shown to correlate with disease severity (Garito et al., 1995). Clinical treatment
of periodontitis significantly reduces PAF levels in the crevicular fluid and improves
periodontitis suggesting that PAF may be an important inflammatory mediator in this
disease (Rasch et al., 1995). LAgP subjects possess low levels of PAFAH, the enzyme
that catabolyzes PAF (Al Darmaki et al., 2003)(Figure 8) and have elevated PAF
synthesis (Shin et al., 2007). This suggests that low levels of PAFAH and elevated PAF
result in the persistence of the inflammation and that these factors play an important role
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in the pathogenesis of LAgP. In addition to the atypical levels of PAFAH and PAF, the
monocytes of AgP subjects exhibit abnormalities associated with monocytes. LAgP
monocytes have a propensity to differentiate into DC compared to the largely
macrophage population that arises from NP monocytes (Barbour et al., 2002c).
Monocytes from both LAgP and GAgP subjects are hyper responsive to LPS compared to
NP monocytes producing TNFα and PGE2 in exceedingly high quantities (Offenbacher
and Salvi, 1999;Shapira et al., 1994).
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Figure 8: PAFAH Activity is Lower in Subjects with LAgP Compared to NP
Subjects. Monocytes from five LAgP (Localized Aggressive Periodontitis, previously
known as Localized Juvenile Periodontitis) and six NP (non-periodontitis) were cultured
in human serum for four days. PAFAH activity was quantified from cell homogenates.
Data shown are the mean ± standard error of four subjects in each group (p<0.05).
Modified from Al-Darmaki et al., Journal of Immunology, 2003 (Al-Darmaki et al.,
2003).
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1.17 Periodontitis and Atherosclerosis
Recent epidemiological data have revealed that there is an increased incidence of
atherosclerosis in periodontitis patients (Elter et al., 2003c;Grau et al., 2004a). Both
periodontitis and atherosclerosis are diseases of chronic inflammation. CP has been
associated with increased risk of coronary heart disease and stroke (Beck et al.,
1996;Elter et al., 2003b). Periodontal disease has a tendency to be more severe in stroke
patients compared to controls (Dorfer et al., 2004;Grau et al., 2004b). Measures of
periodontitis such as periodontal pocket depth have been shown to correlate with elevated
cholesterol and LDL levels (Emingil et al., 2000). Periodontitis has also been
demonstrated to decrease the level, and antiatherogenic potency of HDL (Pussinen et al.,
2004). P.gingivalis infection of apoE null mice results in the exacerbation of
atherosclerosis (Lalla et al., 2003). Chronic periodontitis is associated with elevated
plasma concentrations of the pro-inflammatory cytokine IL-6 that is also elevated in
atherosclerosis (Monteiro et al., 2009). Periodontal disease is also associated with the
induction of a variety of inflammatory cytokines and mediators such as TNFα and PGE2
that have the potential to impact upon atherosclerosis development (Offenbacher and
Salvi, 1999;Shapira et al., 1994). Recently Rufail et al., revealed that GAgP subjects
possess a more atherogenic lipoprotein profile than non-periodontitis (NP) subjects
(Rufail et al., 2005). LDL particle size in GAgP patients was statistically lower than in
NP subjects suggesting a prevalence of the atherogenic small dense LDL. These subjects
also have lower LDL-associated PAFAH activity than non-periodontitis subjects (Rufail
et al., 2005).
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Antiphospholipid syndrome (APS) is an autoimmune disorder characterized with
thrombosis and cardiovascular disease (Ames et al., 2005). It is caused by the
autoimmune production of antibodies against phospholipid. In the general population,
this disorder is observed in one to five percent of healthy adults (Petri, 2000), however a
significantly larger proportion of periodontitis patients have APS (Schenkein et al.,
2003a). Anti-CL is detected in 16.2 percent of chronic periodontitis- and 19.3 percent of
GAgP subjects (Schenkein et al., 2003b). APS is associated with antibodies against
oxidized phospholipids and complexes of cardiolipin and β2 glycoprotein I. Anticardiolipin antibodies are associated with thrombosis risk (Galli et al., 2003). C-reactive
protein (CRP) binds oxLDL, an act that is hypothesized to mediate oxLDL opsonization
through binding of the Fc receptor would potentially lead to the formation of foam cells.
Periodontitis patients also have anti-cardiolipid antibodies that are largely directed
against the complex of cardiolipin and β2-glycoprotein I (Schenkein et al., 2003b).
Phosphorylcholine-bearing strains of oral bacteria and oxLDL react with anti-PC IgG
from human serum (Schenkein et al., 2001). This implies that antibodies directed at
periodontal bacteria cross-reacts with oxidized phospholipids to increase the opsonization
of oxLDL thereby increasing foam cell formation and promoting atherosclerosis
progression. Despite the strong correlative evidence, odds ratios demonstrate just a
modest correlation between periodontal disease and atherosclerosis overall (Grau et al.,
2004b). However, as discussed these associations may be stronger within types of
periodontal diseases and there are a variety of common factors between periodontitis and
atherosclerosis. For example, treatment of periodontitis reduces the anti-atherogenic
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potential of HDL and reduces C-reactive protein (Pussinen et al., JLR, 2004). More
recent studies indicate that in the long-term HDL cholesterol is increased and LDL
cholesterol decreased following periodontal treatment of periodontitis patients (Buhlin et
al., 2009). This further underscores the link between periodontitis and atherosclerosis and
suggests that further research is warranted.

52

CHAPTER TWO: THE REGULATION OF PLATELET ACTIVATING FACTOR
ACETYLHYDROLASE BY OXIDIZED PHOSPHOLIPIDS

2.1 INTRODUCTION

Atherosclerosis is a chronic inflammatory disease involving lipid accumulation in the
vessel wall (Ross, 1999). Transcytosis of Low Density Lipoprotein (LDL) to the arterial
intima results in binding to resident proteoglycans. The oxidative modification of LDL
that ensues generates a spectrum of bioactive oxidized phospholipids (oxPL) (Tsoukatos
et al., 1997). 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) is the
most abundant arachidonyl-containing phospholipid present upon the LDL particle
(Podrez et al., 2002a). Oxidized PAPC (oxPAPC) is a component of minimally modified
LDL that has been measured in atherosclerotic lesions (Subbanagounder et al., 1999) and
characterized extensively with respect to its proatherogenic biological activities (Birukov
et al., 2004b;Huber et al., 2006;Lee et al., 2000). oxPAPC comprises numerous bioactive
lipid mediators notably 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine
(POVPC), 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) and epoxyisoprostane-PC (PEIPC) (Leitinger, 2003;Subbanagounder et al., 2002c). OxPAPC and
its constituents have been shown to mediate many pro-atherogenic events including
adhesion, chemotaxis and differentiation of monocytes (Frostegard et al., 1997a) and
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activation of endothelial cells (Subbanagounder et al., 1999;Yeh et al., 2004). These
events and the subsequent uptake of oxidized LDL (oxLDL) by monocyte-derived cells
represent the earliest events in atherosclerosis (Matsuura et al., 2006).

Platelet activating factor acetylhydrolase (PAFAH) is a phospholipase A2 enzyme that
catabolyzes the pro-inflammatory lipid platelet activating factor (PAF) and oxPL with
short-chain moieties at the sn-2 position. PAFAH is produced by monocyte-derived cells;
macrophages (MO) and dendritic cells (DC) (Al Darmaki et al., 2003). Following release
from the cell, PAFAH associates with LDL and hence has been given the name
lipoprotein-associated phospholipase A2 (LpPLA2). Although PAFAH catabolizes
proatherogenic oxLDL and oxPL, the products of the PAFAH reaction are also
proinflammatory and can exacerbate atherosclerosis (Ninio et al., 2004c). There is
considerable evidence that PAFAH correlates with increased incidence and severity of
coronary artery disease (Stafforini et al., 1987a;Stafforini et al., 1997a). PAFAH is
strongly expressed in the early atheroma but is relatively low in advanced lesions
(Kolodgie et al., 2006). Phase III clinical trials of the inhibitor Darapladib demonstrate
that suppression of the PAFAH activity results in a transient decrease in circulating CRP
and IL-6 and also reduces necrotic core progression (Wilensky et al., 2008). These data
suggest that PAFAH plays an important role in the progression of atherosclerosis.

Despite significant evidence linking PAFAH to atherosclerosis, signaling mechanisms
that induce PAFAH in disease remain elusive. The PAFAH promoter contains a proximal
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putative GAS sequence that could be targeted by pro-inflammatory cytokines (Cao et al.,
1998c). PAFAH transcription is induced by lipopolysaccharide (LPS), likely through
both Sp1 and transcription factors activated by LPS-induced proinflammatory cytokines
(Wu et al., 2004). PAF stimulates PAFAH transcription in HEK cells stably expressing
the PAF-R (Cao et al., 1998b). Some species of oxPL are “PAF-like” because they are
substrates for PAFAH and bind the PAF receptor. As oxPL are co-localized with
PAFAH-producing monocyes in developing atheromas, we hypothesized that the high
levels of PAFAH in atherosclerosis are a consequence of oxPL-induced PAFAH
production.
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2.2 MATERIALS AND METHODS

2.2.1 Materials
Buffy coat was purchased from Virginia Blood Services (Richmond, VA). THP-1 human
monocytes were purchased from the American Type Culture Collection (Manassas, VA).
oxPAPC and its fractions were prepared as described previously (Birukov et al., 2004a)).
IL-6, M-CSF, GM-CSF and IL-4 were all from RnD Systems (Minneapolis, MN). [3H]PAF was purchased from New England Nuclear/PerkinElmer (Boston, MA). 1-alkyl-2acetyl-sn-glycero-3-phosphocholine (PAF), 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero3-phosphocholine

(POVPC),

1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine

(PGPC) and 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (PAPC) were
purchased from Avanti Polar Lipids (Alabaster, AL). AH6809 was purchased from
Biomol (Plymouth Meeting, PA). Lipopolysaccharide (LPS) and Fetal Calf Serum were
purchased from Sigma (St Louis, MO). Human Serum was from Cambrex (Walkersville,
MD). Lymphocyte separation medium was from MP Biomedicals (Solon, OH).
Butaprost, BW245C, BWA868C and PAFAH antibody were purchased from Cayman
Chemicals (Ann Arbor, MI). RT-PCR primers were purchased from Integrated DNA
Technology (Coralville, IA). ERK1/2 antibody was purchased from Cell Signaling
(Danvers, MA).
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2.2.2 THP-1 Monocyte Culture
THP-1 human monocytes were maintained in RPMI with 10% Fetal Calf Serum with
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. THP-1 monocytes
were maintained between 2x105/ml and 1x106/ml, were fed approximately every two
days and passaged at least once a week. Cells were passaged to 2x105/ml the day
previous to treatment with viability at the onset of experiments typically greater than
98%. Cells were maintained under standard cell culture conditions at 37°C and 5% CO2
and were stimulated in serum-free media.

2.2.3 Primary Cell Culture and Differentiation
Approximately 40ml of Buffy coat was diluted with 40ml RPMI. Diluted buffy coat was
layered on a ficoll gradient then centrifuged for 30 minutes at 300g at 20°C. The fuzzy
mononuclear layer was washed three times with RPMI and centrifugation at 1500g for 10
minute washes. Each time the supernatant was removed and the pellet washed again.
After three washes the pellet was resuspended in RPMI supplemented with 10% Human
AB Serum. Cells were plated at a density of 107 per well in 6 well plates and incubated
for 1-2 hours at standard cell culture conditions. Supernatant and non-adherent cells were
removed and monolayer was washed 3 times with plain RPMI. Monocytes were treated
in serum-free media at this point. Other monocytes were induced to differentiate with
cytokine for 7 days into DC with 800U/ml GM-CSF and 500U/ml IL-4 in RPMI with
10% Fetal Calf Serum or into Macrophages with 1000U/ml M-CSF in RPMI with 10%
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Human Serum. Macrophage and Dendritic cell RPMI media was also supplemented with
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin.

2.2.4 Isolation of Low-Density Lipoprotein
Human peripheral blood was drawn after an overnight fast and collected in five, 10ml BD
vacutainers with K3 EDTA. Blood was divided equally into two centrifuge tubes and
centrifuged at 3,000g for 20min at 4°C. Plasma was collected after this first
centrifugation and was supplemented with 500ul Protease I inhibitor NaN3 (0.02%) and
EDTA (1mM). Plasma was mixed with stock density solution then transferred to two
centrifuge tubes. An overlay of stock density solution was added to the tube. Samples
were centrifuged at 45,000rpm at 20°C for 20 hours. After the first centrifugation, the
upper cloudy layer of VLDL was removed. The infranatant density was checked using a
refractometer to ensure it was between 1.015 and 1.017. Once this certain, the remaining
infranatant was removed and the pellet resuspended. Stock density solution was added
and the overlay added over the top. Samples were centrifuged for a further 45,000rpm at
20°C for another 20 hours. At the end of this time, the upper cloudy layer of LDL was
removed from the tubes. Density of infranatant was checked as 1.063 then LDL stored
under argon/nitrogen at 4°C until use.

2.2.5 Protein Assay of Low Density Lipoprotein
Protein concentration was determined using a modified Lowry method with a BSA
standard (Miwa et al., 1988). Reagent A was made with 20ml CTC reagenet, 40ml 5%
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SDS solution and 20ml 0.8M NaOH. Reagent B was Folin Reagent diluted 1:6 with H20.
Dialyzed LDL or BSA were incubated with 0.5ml Reagent A for 10 minutes at room
temperature. Then 0.25ml Reagent B was added, mixed and incubated at room
temperature for 30 minutes. At this point absorbance was measured in a
spectrophotometer at 750nm against blank.

2.2.6 Oxidation of Low Density Lipoprotein
LDL was dialyzed before oxidation or before incubation with cell cultures using dialysis
membrane in phosphate buffered saline with a stir bar present overnight in a cold room.
LDL was preserved in its native form (nLDL) or oxidized by exposure to air or with
2.5μM CuS04 as described previously (Anthonsen et al., 2000b) to produce oxidized LDL
(oxLDL). LDL preparations were supplemented with NaN3 and EDTA post-oxidation to
preserve and protect against further modification. Conjugated dienes were determined by
spectrophotometric analysis of 50µg/ml LDL preparations at 234nm (nLDL<0.1,
mmLDL=0.2, moxLDL=0.4, oxLDL=0.6, soxLDL=1.0). LDL was extensively dialyzed
against PBS before incubating with cells. Cell cultures were treated with 50μg/ml LDL
for 16 hours.

2.2.7 Platelet Activating Factor Acetylhydrolase Activity Assays
Substrate consisted of 50uM 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine with 0.05 µCi
of

hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine,

1-O-[acetyl-(N)-3H]

(NEN/PerkinElmer; 13.5 Ci/mmol) added as a tracer. Substrate was incubated with
59

conditioned medium (enzyme source) and incubated for 30 minutes at 37°C. PAFAH
activity was determined as release of [3H] acetate as quantified by scintillation counting.

2.2.8 RNA Isolation and Platelet Activating Factor Acetylhydrolase Quantitative
Real-Time PCR
RNA was isolated with the Trizol reagent (Invitrogen). PAFAH specific primers were
used to amplify product and normalized to 18S rRNA. PAFAH mRNA was measured by
quantitative real time PCR (qPCR). PAFAH and 18S specific primers and Taqman
probes

were

as

follows;

PAFAH

probe

5’atgatcgccttgacaccctttgga-3’,

sense

5’tgcgtttatattatccatcccaa-3’ and antisense 5’agttgtcattgcaccaaagagt-3’. 18S probe
5’cgagccgcctggataccgcagc-3’,

sense

5’aaaattagagtgttcaaagcaggc-3’

and

anti-sense

5’cctcagttccgaaaaccaacaa-3’. In IL-6 qPCR experiments cDNA was generated using the
High Capacity RNA to cDNA kit from ABI. The IL-6 Gene Expression Assay kit was
used to quantify IL-6 mRNA. All real time PCR reactions were performed with the
TaqMan® One-Step kit from ABI on an ICycler instrument from BioRad.

2.2.9 Reverse Transcriptase PCR
Total RNA isolated with the Trizol reagent (Invitrogen) was used to make cDNA using
the ThermoScript kit from Invitrogen. cDNA was subjected to 30 cycles of PCR
amplification (EP2: 94°C 30seconds, 58°C 30 seconds, 68°C 1 minute. DP1: 94°C 30
seconds, 62°C 30 seconds, 68°C 1min) using the Invitrogen Accuprime Taq DNA

60

Polymerase Kit. RT-PCR Products were analyzed using agarose gel electrophoresis.
Expected product sizes were as follows: EP2 175bp, DP1 284bp.

2.2.10 siRNA experiments
THP1 monocytes cultured in antibiotic-free RPMI prior to all siRNA experiments. 5 x
105 THP1 monocytes in plain RPMI were seeded in 24 well plates. Cells were transfected
with 100nmol IL-6 pool siRNA or non-targeting pool siRNA and Lipofectamine 2000 as
per manufacturer’s instructions (1ul per treatment). Cells were incubated for 16 hours
then supplemented with serum to 10%. Serum was withdrawn 8 hours later and indicated
stimuli were added to the wells and incubated for a further 16 hours before harvesting.
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Sense

5’tgcgtttatattatccatcccaa-3’

PAFAH Anti-Sense 5’agttgtcattgcaccaaagagt-3’

18S

DP1
EP2

Probe

5’atgatcgccttgacaccctttgga-3’

Sense

5’aaaattagagtgttcaaagcaggc-3’

Anti-Sense 5’cctcagttccgaaaaccaacaa-3’
Probe

5’cgagccgcctggataccgcagc-3’

Sense

5’tcgggaagttcgtgcagtactgcc-3’

Anti-Sense 5’gatccagctcctccaggggctgag-3’
Sense

5’caacctcatccgcatcgacc-3’

Anti-Sense 5’Caaggagcagacggcgaagg-3’

Table 4: Primer and Probe Sequences
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2.2.11 Western Blots
Cells were washed once with PBS then homogenized in RIPA buffer with protease
(Roche Complete Mini) and phosphatase inhibitors. Equal amounts of protein were
separated by SDS-polyacrylamide gel electrophoresis, blocked in 5% non-fat dried milk,
and incubated overnight in primary antibody. Blots were developed with HRP coupled
secondary antibodies and the enhanced chemiluminescent (ECL) detection kit
(Amersham Bioscience) or Femto (Pierce).

2.2.12 Il-6 ELISA
IL-6 ELISA kit from BD was followed as per manufacturer’s instructions with neat
supernatants from oxPL-treated cells.

2.2.13 Flow Cytometry
Differentiated macrophages or dendritic cells or THP1 monocytes were incubated and
stained with PE-anti-IL-6R or PE-anti-isotype matched control for 30 minutes at 4°C.
Cells were washed three times in PBS then analyzed using the FACScan (Becton
Dickinson) instrument.

2.2.14 Statistical Analyses
Data are presented as mean +/- standard deviation. Student t-tests were performed and
statistical significance is expressed as *P<0.05, **P<0.01, ***P<0.001.
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2.3 RESULTS

2.3.1 Oxidized Phospholipids Induce Platelet Activating Factor Acetylhydrolase in
Monocytes and Dendritic Cells but not Macrophages

Other investigators have demonstrated that oxidized 1-palmitoyl-2-arachidonyl-snglycero-3-phosphocholine (oxPAPC) activates monocytes and induces expression of
proinflammatory cytokines (Furnkranz et al., 2005d;Yeh et al., 2004). We sought to
determine whether oxPAPC would also stimulate PAFAH expression. To test this
hypothesis monocytes and monocyte-derived cells were treated with native PAPC or
oxPAPC and PAFAH expression analyzed by quantitative RT-PCR. Native PAPC had no
effect on PAFAH expression but LPS, a well-known inducer of PAFAH strongly
elevated PAFAH mRNA in primary monocytes, the THP-1 human monocytic cell line
and monocyte-derived dendritic cells (DC) and macrophages (MO) (Figure 9). In
contrast, although oxPAPC robustly induced PAFAH expression by THP-1 monocytes
(5.7-fold, p<0.001), primary monocytes (2.4-fold, p<0.05), and DC (2.6-fold, p<0.01),
MO were unresponsive to oxPAPC with no significant change in PAFAH expression or
activity (Figures 9D, 9F). Like primary monocytes and DC, THP1 monocytes were
highly responsive to both LPS and oxPAPC. Therefore, THP1 monocytes were used as a
surrogate for primary cells to avoid subject-to-subject variation in the response to
oxPAPC.
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Figure 9: Oxidized Phospholipids Induce Platelet Activating Factor Acetylhydrolase
in Monocytes and Dendritic Cells but not Macrophages. Cells were treated for 16
hours with 50µg/ml PAPC, 50µg/ml oxPAPC or 100ng/ml LPS and PAFAH quantified
by qPCR (A-D) in (A) THP-1 monocytes, (B) primary human monocytes (C) dendritic
cells and (D) macrophages. PAFAH catalytic activity was analyzed in (E) dendritic cells
and (F) macrophages. Responses relative to control treatments were determined and data
represent the mean of 3-5 independent experiments. *p<0.05, **p<0.01, ***p<0.001.
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2.3.2 PEIPC-Rich Fractions of oxPAPC Induce PAFAH Expression and Activity

OxPAPC is comprised of an array of lipid species that differ in the degree of oxidation/
fragmentation of the sn-2 acyl-chain as well as their effects on monocytes and other cells
(Bluml et al., 2005b;Leitinger et al., 1997;Pegorier et al., 2005;Yeh et al., 2004). To
identify the species responsible for PAFAH induction, oxPAPC was separated on the
basis of sn-2 acyl chain length into fractions designated as short-chain (m/z <782.7, rich
in PAF-like lipids) or long-chain (m/z > 782.7, enriched with PEIPC and other
epoxyisoprostanes). The short chain fraction had no effect on PAFAH expression in
THP1 monocytes or DC but long chain oxPAPC lipids induced PAFAH expression by
approximately 5-fold in DC and 2.5-fold in THP1 monocytes (Figure 10A). As predicted,
neither short- or long-chain fractions of oxPAPC altered PAFAH expression in
macrophages (Figure 10A). DC were also stimulated with purified components of the
short-chain oxPAPC fraction; POVPC and PGPC (Figure 10B). POVPC did not
significantly alter PAFAH expression from control levels (Figure 10B). PGPC
significantly induced PAFAH expression, however this was modest at best (~1.8-fold,
p=0.04) and could account for the robust induction of PAFAH expression that was
observed following oxPAPC stimulation. The strong PAFAH induction in DC in
response to 10µg/ml long-chain oxPAPC lipids led us to further investigate the sensitivity
of these cells to long-chain oxPAPC. As little as 5ng/ml of the long-chain fraction of
oxPAPC was sufficient to significantly induce DC PAFAH expression (Figure 10C). This
series of experiments also revealed that the sensitivity of DC to long-chain lipids is not
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constant. The experiment in Figure 2C reveals a maximal induction of PAFAH at
0.5µg/ml (approximately 4-fold) in comparison to 10µg/ml in Figure 10A (approximately
5-fold). The maximum fold induction observed between these series of experiments is,
however comparable. To further emphasize the role of PEIPC in the induction of
PAFAH, UV-treated PAPC was used as an independent test. Treatment of PAPC with
UVA-1 (340-390nm) is an alternative method by which to produce a lipid fraction that is
rich in PEIPC (Gruber et al., 2007). DC treated with 2µg/ml or 10µg/ml UV-PAPC for 16
hours responded with a significant induction of PAFAH (1.96-fold at 2µg/ml; Figure
10C).
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Figure 10: Long-chain Oxidized Phospholipids Induce PAFAH Expression. A. DC,
THP-1 Monocytes and Macrophages were treated with short- or long-chain fractions
derived from 10µg/ml oxPAPC for 16 hours. B. DC were treated with 10µM POVPC or
PGPC for 16h then PAFAH expression was quantified from RNA. C. DC were treated
with various concentrations of long-chain fractions of oxPAPC for 16 hours D. Dendritic
cells were stimulated with PEIPC-containing fractions of lipids prepared by UVoxidation at either 2µg/ml or 10µg/ml for 16 hours. PAFAH expression is expressed as
fold relative to vehicle control. Responses relative to control treatments were determined
and data are the mean of 3 independent experiments (A-C) or a single experiment (D).
*p<0.05, **p<0.01, ***p<0.001.
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2.3.3 Signaling through EP2 and DP1 are required for PAFAH induction by Long
Chain oxPAPC

PEIPC, the best characterized of the long-chain species of oxPAPC (Subbanagounder et
al., 2000;Subbanagounder et al., 2002b), binds the prostaglandin receptors DP1 and EP2
(Li et al., 2006a);. As shown in Figure 11A, both of these receptors are expressed by
monocytes and monocyte-derived DC and MO. We next tested the hypothesis that
oxPAPC induces PAFAH through DP1 and/or EP2. THP-1 monocytes and DC were
incubated with selective agonists for EP2 (Butaprost, Figure 11B-C) or DP1 (BW245C,
Figure 11E-F). Both agonists induced PAFAH in THP1 cells and DC in a dosedependent manner. Treatment of macrophages with 1uM Butaprost did not elicit a
response (Figure 11D). In addition, a selective antagonist of DP1 suppressed oxPAPCmediated induction of PAFAH by greater than 75% (Figure 11G). Together, these data
suggest that long chain lipids in oxPAPC induce PAFAH primarily through the
prostaglandin receptors EP2 and DP1.
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Figure 11: Prostaglandin Receptor Subtypes DP1 and EP2 are Required for
Optimal PAFAH Induction by long-chain oxidized phospholipids. A. EP2 and DP1
expression was measured by reverse transcriptase PCR. Data shown is representative of 3
independent experiments. B-F PAFAH expression was analyzed in THP-1 monocytes
following 16 hour treatments. B. THP1 Monocytes were treated with 0.01, 0.1 or 1uM
Butaprost. C. DC were treated with 0.01, 0.1 or 1uM Butaprost. D. Macrophages were
treated with 1uM Butaprost. E. DC were treated with BW245C. F. THP-1 Monocytes
were treated with BW245C. Responses are expressed relative to control treatments.
*p<0.05, **p<0.01, ***p<0.001.
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Figure 11: Prostaglandin Receptor Subtypes DP1 and EP2 are Required for
Optimal PAFAH Induction by long-chain oxidized phospholipids G.THP1 monocytes
were pre-treated with 0.01, 0.1, 1uM BW A868C (G) or 10uM AH6809 (H) for 30
minutes before stimulation with 10µg/ml long-chain fraction of oxPAPC. Cells were
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percentage of optimal PAFAH induction where “0” treatment is treatment with longchain oxpapc fraction in the absence of inhibitor. The mean of two independent
experiments ± std dev is shown. *p<0.05, **p<0.01, ***p<0.001.
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2.3.4 IL-6 Induces PAFAH Expression

The PAFAH 5’ flanking region contains a canonical γ-interferon activation site (GAS)
sequence (598TTCAGAGAA606) that has the potential to bind the transcription factor Stat
3. Several recent reports have shown that prostaglandin E2 (PGE2) induces interleukin 6
(IL6) production and/ or augments STAT3 activation by IL6 (Cheon et al., 2006a;Han et
al., 2006b;Liu et al., 2002c). Butaprost, the selective EP2 agonist, induces IL-6
production by macrophages (Chen et al., 2006) and our data demonstrate that IL-6 is
induced by the selective DP1 agonist BW245C as well (Figure 12A). Based on these
studies, we hypothesized that PAFAH induction by oxPAPC would be mediated through
IL-6. To test this hypothesis, we first performed experiments to determine if the oxPL
induce IL-6. The long-chain fraction of oxPAPC stimulated IL-6 production by THP1
monocytes (Figure 12A). Exogenous IL-6 mimicked the effects of oxidized lipids and
induced PAFAH expression by ~2-fold which was comparable to induction by the
canonical PAFAH inducer LPS (Figure 12B). IL-6 also induced PAFAH in a timedependent manner in THP1 monocytes and DC (Figure 12D and F). Importantly,
oxPAPC and in particular long-chain fractions stimulate IL-6 production in a manner that
precedes that of PAFAH (Figure 12C-E). Together, these data support the hypothesis
that IL-6 is upstream of PAFAH induction in oxPAPC-stimulated monocytes. To confirm
this hypothesis, we quantified PAFAH expression in oxPAPC-stimulated THP1 cells that
were pretreated with siRNA directed against IL-6 (Figure 12F). IL-6 siRNA significantly
suppressed induction of PAFAH by the long-chain fraction of oxPAPC (Figure 12E, p =
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0.03; n=2). These data demonstrate that IL-6 is required for optimal PAFAH expression
in response to oxPAPC.
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Figure 12: Interleukin 6 Induces PAFAH Induction. A. Dendritic cells were treated
with BW245C 0.1υM or oxPAPC 10µg/ml for 16hours. Secreted IL-6 protein was
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THP-1 monocytes were stimulated with exogenous IL-6 for 3- or 6-hours and PAFAH
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analyzed for IL-6 expression via qPCR. Responses relative to control treatments were
determined and data represent the mean of 3 (A-D) Data in Panel B was generated by
Minkyeong Son, Experiment in Panel D was conducted by Minkyeong Son from samples
generated by Rachael Griffiths. *p<0.05, **p<0.01, ***p<0.001.
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Figure 12: Interleukin 6 Induces PAFAH Induction. E. THP-1 monocytes treated with
siRNA directed against IL-6 were stimulated with 10µg/ml oxPAPC. PAFAH expression
was analyzed at 16 hours. F. DC treated with oxPAPC over a 48h period were harvested
and IL-6 secretion and PAFAH expression analyzed. Responses relative to control
treatments were determined and data represent the mean 2 independent experiments (E),
or a single experiment (F). *p<0.05.
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2.3.5 IL-6 Receptor Expression May Limit PAFAH Induction in Macrophages

While oxPAPC upregulates PAFAH in monocytes and monocyte-derived DC, MO do not
respond in this manner (Figure 9D,9F and 9B). This observation suggests that
macrophages lack an essential component of the signaling machinery necessary to make
this response. As illustrated in Figure 11A, MO express DP1 and EP2, the prostaglandin
receptors that bind long chain lipids in oxPAPC and induce PAFAH. Therefore, we
focused our attention on events downstream of prostaglandin receptors and performed
experiments to compare IL-6 receptor (IL-6R) expression in MO and DC. As shown in
Figures 13A-C, cell surface expression of IL6-R was considerably lower on MO in
comparison to THP-1 monocytes and DC. To confirm these data, we compared IL-6
receptor expression in whole cell homogenates by Western blot. While IL6-R was readily
detected in homogenates of DC and THP cells, we were unable to detect IL-6R in
macrophage homogenates (Figure 13D). Importantly, although PAFAH was readily
induced when THP1 monocytes or DC were stimulated with exogenous IL-6, MO
responded more modestly (Figure 13E). These data suggest that the ability of MO to
induce PAFAH in response to oxPAPC is limited by their low expression of IL6-R.
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2.3.6 The Induction of PAFAH by oxPAPC May Be Mediated by Stat3

IL-6 binding to its receptor leads to the activation of Signal Transducer and Activator of
Transcription 3 (Stat3) (Han et al., 2006a). PAFAH contains a canonical Stat-binding
GAS element and could therefore be transcriptionally regulated by Stat. We next tested
whether Stat3 was involved in the regulation of PAFAH by oxPAPC. DC were treated
with oxPAPC over 8 hours and the activation of Stat3 was assessed at various times by
measuring phosphorylation of this transcription factor. Stat3 tyrosine and serine
phosphorylation was elevated at 4 hours in DC treated with oxPAPC versus vehicle
(Figure 13F) suggesting that Stat3 is activated by oxPAPC.
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2.3.7 Mildly Oxidized LDL Induces PAFAH Expression

PAPC is the most abundant arachidonyl-containing phospholipid in LDL and the major
oxidized phospholipid species associated with oxPAPC have been identified in a mildly
oxidized LDL (Watson et al., 1997a). We next performed experiments to determine
whether LDL-associated oxPL would induce PAFAH. LDL-associated PAFAH activity
was first inhibited using Pefabloc (Figure 14A). Excess inhibitor and salts were removed
by dialysis, then oxidized preparations of LDL were generated by incubating native LDL
with air or CuS04 at 37oC (methods). Five species of LDL were produced that ranged in
their oxidation level from native, or unmodified (nLDL) to extensively oxidized
(eoxLDL). The range of oxidation levels was measured by analyzing conjugated diene
formation at 234nm (Figure 14B). Preliminary experiments revealed a mildly oxidized
LDL preparation was the sole species generated that could significantly alter PAFAH
expression (Figure 14C). Further research revealed that this species of oxLDL
significantly induced PAFAH expression in monocyte-derived DC but not in MO. These
observations are consistent with effects of oxPAPC on PAFAH expression in MO and
DC (Figure 9) and supported the hypothesis that oxLDL-associated oxPL induce
PAFAH in early atheromas.
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Figure 15: Model of Long-Chain oxPL Regulation of PAFAH Expression
OxPAPC and its constituent PEIPC are present upon oxLDL particles. These oxPL bind
the prostaglandin receptor subtypes EP2 and DP1 triggering the induction of IL-6
expression. IL-6 protein is secreted from the cell and binds its receptor (IL-6R). This
activates Stat3 allowing its translocation to the nucleus and binding to GAS element in
the PAFAH 5’ region. We hypothesize that this initiates PAFAH transcription and hence
increased PAFAH protein.
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2.4 DISCUSSION

OxPAPC and other oxPL have a variety of effects that are central to the development and
progression of atherosclerosis including activation of endothelial cells, smooth muscle
cells and macrophages (Cherepanova et al., 2009;Pegorier et al., 2005;Subbanagounder et
al., 2002a). Our studies are the first to demonstrate that oxPAPC induces PAFAH, the
lipoprotein-associated PLA2.

OxPAPC and its component lipids were originally

identified in a mildly oxidized preparation of LDL (Watson et al., 1997a). We
demonstrate that mildly oxidized LDL induces PAFAH to levels comparable to those
achieved with oxPAPC. Importantly, our data suggest that oxPAPC and oxLDL induce
PAFAH through similar mechanisms, as monocytes and DC respond to both stimuli but
neither oxPAPC nor oxLDL induce PAFAH in macrophages. Together, these data
underscore the physiological relevance of oxPAPC-mediated PAFAH induction and
support the hypothesis that oxLDL-activated monocytes are responsible for the high
levels of PAFAH in atherosclerosis.

Other investigators have shown that PAF induces transcriptional activity of a PAFAH
reporter construct in COS cells (Cao et al., 1998a). Based on those observations, we
hypothesized that PAF-like lipids in the short chain fraction of oxPAPC would induce
PAFAH. Contrary to our expectations, short chain, PAF-like lipids have no effect on
PAFAH. The short chain fraction contains a variety of lipid species, only some of which
are PAF-like and bind the PAF receptor (Pegorier et al., 2005). It is possible that other
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lipids in the short chain fraction antagonize effects of PAF-like lipids resulting in no net
increase in PAFAH expression. Alternatively, PAF-mediated induction of PAFAH may
be cell-type specific.

Our studies indicate that lipids in the PEIPC-containing long-chain fraction of oxPAPC
induce PAFAH. These lipids bind a variety of receptors, including the VEGF receptor,
toll-like receptors, and the prostaglandin receptors EP2 and DP1 (Li et al., 2006a;Walton
et al., 2003a;Zimman et al., 2007). As monocytes express EP2 and DP1 and are known to
be activated by prostaglandins (Hata and Breyer, 2004), we tested the hypothesis that the
long chain fraction of oxPAPC induces PAFAH through these receptors. Both EP2 and
DP1 agonists induced PAFAH expression. Conversely, oxPAPC-mediated PAFAH
induction was suppressed by a DP1 receptor antagonist. Neither inhibitor completely
blocked PAFAH induction, suggesting that both prostaglandin receptors are involved in
this response to oxPAPC. Together, these studies indicate that monocytes produce
PAFAH in early atheromas when they are activated by epoxyisoprostanes from mildly
oxLDL.

EP2 and DP1 are G protein-coupled receptors that signal through Gs and activate
adenylyl cyclase and other signaling pathways (Hata and Breyer, 2004). Like
prostaglandins, the long chain oxPL PEIPC augments cytosolic cAMP (Cole et al., 2003).
Although these observations suggest that oxPAPC increases PAFAH transcription
through CREBP, there is no evidence for a cyclic AMP response element (CRE) in the
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PAFAH 5’ flanking region. Prostaglandin E2 (PGE2) and synthetic EP2 agonists induce
interleukin 6 (IL6) production and/ or augment STAT3 activation by IL6 (Chen et al.,
2006;Cheon et al., 2006b;Han et al., 2006c;Liu et al., 2002b). Other investigators have
shown that oxPAPC and oxidized surfactant lipids stimulate interleukin-6 (IL-6)
production and PEIPC activates Stat3, a transcription factor in the IL-6 signaling pathway
(Furnkranz et al., 2005d;Imai et al., 2008;Yeh et al., 2004). These observations prompted
the hypothesis that IL-6 is involved in oxPAPC-mediated PAFAH induction. We report
several lines of evidence supporting this hypothesis, including (a) monocytes generate IL6 in response to stimulation with oxPAPC or the prostaglandin receptor agonists
butaprost and BW245C, (b) IL-6 production precedes that of PAFAH, (c) PAFAH
expression increases when monocytes are treated with exogenous IL-6, and (d) IL6targeted siRNA reduces oxPAPC-mediated PAFAH induction. These observations are
consistent with other reports that IL-6 is required for optimal responses to oxPAPC
(Furnkranz et al., 2005b;Van Lenten et al., 2001b). Notably, the IL-6 5’ flanking region
contains a canonical GAS element (1052-TTCTTGGAA-1060) that could bind activated
Stat3 and our preliminary data indicate that Stat3 is tyrosine- and serine-phosphorylated
in oxPAPC-treated cells (Figure 13). At present, we are performing additional
experiments to delineate the roles of Stat3 and the GAS element in PAFAH induction by
oxPAPC.

Monocytes and DC robustly induce PAFAH in response to oxPAPC.

However,

macrophages did not make this response and their failure to respond was not due to a lack
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of the prostaglandin receptors EP2 or DP1. Although exogenous IL-6 robustly induced
PAFAH in DC, macrophages made a more limited response which prompted the
hypothesis that oxPAPC-mediated PAFAH induction is limited in these cells due to low
expression of IL-6 receptor. Indeed macrophages express almost undetectable levels of
IL-6Rα (Figure 13C). Although MO likely do not secrete significant amounts of PAFAH
in response to oxLDL in early atheromas, it remains possible that they contribute to this
response. MO are activated in response to signaling through the prostaglandin receptors.
As noted above, these receptors signal through adenylate cyclase, leading to increased
cytosolic cAMP. The IL-6 promoter contains a cAMP-responsive element (CRE) and
cAMP is known to induce IL-6 production by monocytes (Dendorfer et al., 1994). Thus,
it is possible that oxPL-activated MO augment PAFAH production by producing IL-6.
Additional experiments are required to test this hypothesis and further delineate the roles
of MO and DC to PAFAH production in atherosclerosis.

Although both monocytes and DC generate PAFAH in response to oxPL, DC are unique
in their ability to produce large amounts of PAFAH in response to IL-6 as well. Like
PAFAH, IL-6 expression is elevated in atherosclerosis lesions (Seino et al., 1994). We
hypothesize that high levels of IL-6 in the atheroma exacerbate effects of oxPL resulting
in chronic activation of DC and the high levels of PAFAH that characterize
atherosclerosis. This is a unique role for DC in the pathogenesis of atherosclerosis, but it
adds to a growing list of studies suggesting that DC may be more important components
of the atheroma than was previously believed. Like macrophages, (the monocyte more
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classically associated with atherosclerosis), immature DC are highly phagocytic and can
engulf large amounts of oxLDL and may become foam cells (Albert et al., 1998). DC are
present at unstable shoulder regions of the plaque (Bobryshev, 2000a) and are proposed
to be involved in plaque maturation and decreased stability of more advanced
atherosclerotic lesions (Bobryshev, 2000d). This is likely related to the almost
unparalleled ability of DC to secrete the proinflammatory cytokines that exacerbate
atherosclerosis. Dendritic cell egress correlates with regression of the developing
atheroma (Angeli et al., 2004c). oxPAPC likely impedes DC emigration by preventing
their maturation into highly motile mature DC (Bluml et al., 2005a). Our studies suggest
an additional effect of oxPAPC-activated DC in the progression of atherosclerosis:
induction of the proatherogenic enzyme PAFAH.

The THP1 monocytic cell line was used primarily as a model for DC in this study. DC
were generated from primary cells which, despite the high concentrations of cytokines
they are differentiated with, have the potential to respond differently from subject to
subject. We observed that THP1 monocytes and DC respond similarly to oxPAPC, longchain fractions and to Butaprost (Figures 9, 10 and 11). However, THP1 monocytes are
more sensitive to BW245C, the DP1 agonist than are DC (Figure 11). Additionally, while
DC are highly sensitive to IL-6, generating 8-fold responses on a consistent basis, THP1
monocytes respond more similarly to macrophages (Figures 12B and 12E). We are
intrigued by this disparity in an otherwise excellent model for the DC. IL-6 Receptor is
highly expressed at the cell surface of THP1 monocytes and in concentrations that dwarf
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the DC. We postulate that this could be a consequence of increased IL-6R expression
following the activation of DC by oxidized phospholipids. Alternatively, there could be
an additional pathway following DP1 activation that is independent of IL-6. Further
investigation is certainly warranted to determine the cause of these different responses.

The role of PAFAH in cardiovascular disease is somewhat controversial. Early studies
suggested that PAFAH is a protective enzyme that limits the induction of atherosclerosis,
likely because it catabolizes pro-atherogenic ox-LDLs and/or protects lipoproteins from
oxidation (Noto et al., 2003a;Stafforini et al., 1997f;Stremler et al., 1989a;Watson et al.,
1997b).

For example, the incidence of myocardial infarction and atherosclerotic

occlusive disease are elevated in Asian subjects with loss of function mutations in
PAFAH (LIU et al., 2006;Yamada et al., 1998a;Yamada et al., 2000a).

In animal

models, PAFAH promotes egress of DC from lesions, reduces neointima formation, and
lessens severity of atherosclerosis (Arakawa et al., 2005a;Quarck et al., 2001c;Turunen et
al., 2005a) (Angeli et al., 2004a). In contrast, most recent studies suggest that PAFAH is
at the very least a marker for vascular disease and may even be pro-atherogenic in
Western populations (Blankenberg et al., 2003b). A growing body of literature indicates
associations between elevated plasma PAFAH and cardiovascular diseases such as
coronary artery calcification, myocardial infarction and ischemic stroke (Ballantyne et
al., 2004b;Ballantyne et al., 2005a;Blake et al., 2001a;Packard et al., 2000a) (Johnston et
al., 2006a;Unno et al., 2000). Although plasma PAFAH necessarily correlates with LDL
levels (Albert et al., 2005), most studies suggest PAFAH as an independent predictor for
87

cardiovascular events (Zalewski and Macphee, 2005b). The relative risk associated with
elevated PAFAH is relatively modest, typically in the range of ~2.0. In Phase III clinical
trials, a selective inhibitor of PAFAH (Darapladib) reduced plasma CRP and IL-6 and
slowed progression of the necrotic core (Wilensky et al., 2008). Together, these data
suggest that PAFAH has an active role in the progression of atherosclerosis, likely related
to products of the PAFAH reaction that are proinflammatory and thereby exacerbate
atherogenesis (Chen, 2004b;Tselepis and Chapman, 2002b). It is possible that the impact
of PAFAH differs in early versus late stages of disease. Induction of PAFAH by mildly
oxidized LDLs in early atheromas may be a protective response intended to limit
accumulation of proatherogenic oxLDL. In more mature lesions, proinflammatory
products of the PAFAH reaction may accumulate and exacerbate disease. Additional
studies are necessary to test this hypothesis and more clearly delineate the role of PAFAH
in pathogenesis of atherosclerosis.

Data from our study and others have correlated oxPAPC with IL-6 signaling and Stat3
activation as well as lesion development in vivo. Our data demonstrate a role for IL-6 in
oxPL-stimulated PAFAH expression. However, there are likely additional consequences
of oxPL-mediated induction of IL-6 within the atheroma. Elevated IL-6 is consistently
measured in atherosclerotic plaques of humans, rabbits and mice and, like PAFAH is
present particularly in the unstable shoulder region of the plaque (Ikeda et al.,
1992;Schieffer et al., 2000;Seino et al., 1994;Sukovich et al., 1998). IL-6 knockout mice
have impaired monocyte recruitment and recombinant IL-6 exacerbates early
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atherosclerosis in ApoE null mice (Huber et al., 1999;Romano et al., 1997). These data
suggest a key role for IL-6 in atherosclerosis development and that long chain oxPL
likely contribute to the pathogenesis of atherosclerosis by promoting IL-6 production by
DC. They also prompt the hypothesis that in addition to its pro-atherogenic role, oxPLstimulated IL-6 may be involved in other diseases. Long-chain oxPL are generated as a
result of oxidative stress associated with a variety of inflammatory diseases and many of
these disorders are induced/ exacerbated by IL-6 (Gruber et al., 2007). Thus, we
anticipate that future studies will show that oxPL-activated DC are associated with
pathogenesis of atherosclerosis as well as further inflammatory diseases.
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CHAPTER III: THE REGULATION OF PLATELET ACTIVATING FACTOR
ACETYLHYDROLASE BY PLATELET ACTIVATING FACTOR

3.1 INTRODUCTION

Platelet activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a
potent pro-inflammatory phospholipid. It is involved in a variety of inflammatory
diseases including acute pancreatitis (Wilson et al., 1998), periodontitis (Emingil et al.,
2001;Garito et al., 1995), sepsis (Zimmerman et al., 2002) and atherosclerosis (Tselepsis
and Chapman, 2002). PAF’s signaling abilities are diverse, inducing a wide range of
inflammatory processes. First identified for its ability in the activation of platelets
(Benveniste, 1974), PAF also induces the production of eicosanoids by macrophages and
the adhesion of activated leukocytes to endothelial cells (Ding et al., 1992;Schaloske et
al., 2005;Stewart et al., 1990). Many of the inflammatory actions of PAF are mediated
through its G-protein coupled receptor (PAF-R) (Honda et al., 2002;Shimizu et al., 1992)
which has been shown to couple to different G protein alpha subunits depending upon the
cell type (Shimizu et al., 1992).

PAF’s actions are terminated upon its enzymatic degradation into lyso-PAF and acetate.
The enzyme responsible for the blunting of PAF’s effects is the monocyte-derived
phospholipase A2, PAFAH. Like PAF, PAFAH is associated with inflammatory diseases
including atherosclerosis and periodontitis (Al Darmaki et al., 2003;Rufail et al.,
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2005;Tselepis and Chapman, 2002a). Despite the consequence of this enzyme in
hydrolyzing PAF and its relative contribution to the resolution of inflammation, its
regulation is poorly understood. Lipopolysaccharide (LPS) induces PAFAH expression in
decidual macrophages and increases PAFAH promoter activity in RAW264.7
macrophages (Narahara et al., 1993;Wu et al., 2004). However, alternative studies have
shown the suppression of PAFAH promoter activity by LPS in RAW264.7 macrophages
(Cao et al., 1998d). We have demonstrated the induction of PAFAH by the inflammatory
cytokine IL-6 in monocytes and DC and to a significantly lesser extent in macrophages
(Figures 12 and 13). However, other investigators have indicated that the RAW264.7
macrophage cell line is unresponsive to IL-6 (Cao et al., 1998d). PAF induces PAFAH
transcriptional activity in human embryonic kidney (HEK) cells stably transfected with
the PAF receptor (Cao et al., 1998d).

PAF-like oxPL such as POVPC and PGPC are present in short-chain fractions of
oxPAPC (Marathe et al., 1999). Importantly, the PAF receptor may mediate the signaling
of PAF-like lipids. Endothelial cell activation by phospholipid oxidation products
including POVPC, is inhibited by the PAF receptor antagonist WEB2086
(Subbanagounder et al., 1999). Additionally, POVPC signals in part through the PAF
receptor on human macrophages (Pegorier et al., 2005). Our data suggest that long-chain,
but not short-chain fractions of oxPAPC induce PAFAH in monocytes and DC (Figure
10). PGPC significantly induces PAFAH in DC but this is does not compare to the robust
induction initiated by long-chain fractions of oxPAPC (Figure 10). While PAF induces
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PAFAH in macrophages (Cao et al., 1998d), POVPC does not significantly alter PAFAH
in DC (Figure 10) despite the expression of the PAF receptor in these cells. We were
intrigued by the diverse responses to these stimuli by cells lines and models used to study
PAFAH. We hypothesized that as bona fide PAF induces PAFAH in HEK cells, the same
response would be observed in monocytes.
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3.2 MATERIALS AND METHODS

3.2.1 Materials:
Buffy coat was purchased from Virginia Blood Services (Richmond, VA). THP-1 human
monocytes were purchased from the American Type Culture Collection (Manassas, VA).
[3H-]PAF was purchased from New England Nuclear/PerkinElmer (Boston, MA). 1alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) and lyso-PAF were purchased from
Avanti Polar Lipids (Alabaster, AL). Lipopolysaccharide (LPS) and Fetal Calf Serum
were purchased from Sigma (St Louis, MO). Human Serum was from Cambrex
(Walkersville, MD). Lymphocyte separation medium was from MP Biomedicals (Solon,
OH). RT-PCR primers were purchased from Integrated DNA Technology (Coralville,
IA).

3.2.2 THP-1 Monocyte Culture
THP-1 human monocytes were maintained in RPMI with 10% Fetal Calf Serum with
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. THP-1 monocytes
were maintained between 2x105/ml and 1x106/ml, were fed approximately every two
days and passaged at least once a week. Cells were passaged to 2x105/ml the day
previous to treatment with viability at the onset of experiments typically greater than
98%. Cells were maintained under standard cell culture conditions at 37°C and 5% CO2
and were stimulated in serum-free media.
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3.2.3 Primary Cell Culture and Differentiation
Approximately 40ml of Buffy coat was diluted with 40ml RPMI. Diluted buffy coat was
layered on a ficoll gradient then centrifuged for 30 minutes at 300g at 20°C. The fuzzy
mononuclear layer was washed three times with RPMI and centrifugation at 1500g for 10
minute washes. Each time the supernatant was removed and the pellet washed again.
After three washes the pellet was resuspended in RPMI supplemented with 10% Human
AB Serum. Cells were plated at a density of 107 per well in 6 well plates and incubated
for 1-2 hours at standard cell culture conditions. Non-adherent cells were removed and
monolayer was washed 3 times with plain RPMI. Monocytes were treated in serum-free
media at this point. Other monocytes were induced to differentiate with cyokines for 7
days into DC with 800U/ml GM-CSF and 500U/ml IL-4 in RPMI with 10% Fetal Calf
Serum or into Macrophages with 1000U/ml M-CSF in RPMI with 10% Human Serum.
Macrophage and Dendritic cell RPMI media was also supplemented with 2mM
Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin.

3.2.4 Platelet Activating Factor Acetylhydrolase Activity Assays
Substrate consisted of 50uM 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine with 0.05 µCi
of

hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine,

1-O-[acetyl-(N)-3H]

(NEN/PerkinElmer; 13.5 Ci/mmol) added as a tracer. Substrate was incubated with
conditioned medium (enzyme source) and incubated for 30 minutes at 37°C. PAFAH
activity was determined as release of [3H] acetate as quantified by scintillation counting.
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3.2.5 RNA Isolation and Platelet Activating Factor Acetylhydrolase Quantitative
Real-Time PCR
RNA was isolated with the Trizol reagent (Invitrogen). PAFAH specific primers were
used to amplify product and normalized to 18S rRNA. PAFAH mRNA was measured by
quantitative real time PCR (qPCR). PAFAH and 18S specific primers and Taqman
probes

were

as

follows;

PAFAH

probe

5’atgatcgccttgacaccctttgga-3’,

sense

5’tgcgtttatattatccatcccaa-3’ and antisense 5’agttgtcattgcaccaaagagt-3’. 18S probe
5’cgagccgcctggataccgcagc-3’,

sense

5’aaaattagagtgttcaaagcaggc-3’

and

anti-sense

5’cctcagttccgaaaaccaacaa-3’. Real time PCR reactions were performed with the
TaqMan® One-Step kit from ABI on an ICycler instrument from BioRad.

3.2.6 Statistical Analyses
Data are presented as mean +/- standard deviation. Student t-tests were performed and
statistical

significance

is

expressed

as
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*p<0.05,

**p<0.01,

***p<0.001.

PAFAH

18S

Sense
AntiSense
Probe
Sense
AntiSense
Probe

5’tgcgtttatattatccatcccaa-3’
5’agttgtcattgcaccaaagagt-3’
5’atgatcgccttgacaccctttgga3’
5’aaaattagagtgttcaaagcaggc3’
5’cctcagttccgaaaaccaacaa3’
5’cgagccgcctggataccgcagc3’

Table 5: Quantitative Real Time PCR Primers and Probe Sequences
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3.2 RESULTS

3.2.1 Platelet Activating Factor Suppresses PAFAH in Dendritic Cells

Monocytes, macrophages and dendritic cells are the primary source of PAFAH in vivo.
Therefore, monocytic cells were used as a model by which to study the regulation of
PAFAH by PAF. Monocytes express low levels of PAFAH however their differentiation
into DC or MO is accompanied by a robust increase in PAFAH expression (Elstad et al.,
1989). Therefore, DC and MO were used as model cells with which to investigate the
regulation of PAFAH by PAF. Differentiated DC and MO were stimulated with PAF for
16 hours before PAFAH was quantified by qPCR or by radiometric activity assay.
PAFAH expression was suppressed by approximately 50 percent in dendritic cells treated
with 100nM PAF (Figure 16 A-B). This decline in PAFAH expression was accompanied
by a similarly reduced level of activity in PAF-treated monocytes (Figure 16B).
Surprisingly, macrophage PAFAH was unaffected by PAF stimulation at both the
expression and activity levels (Figure 16A and B).
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A

B

Figure 16: PAF Suppresses PAFAH Expression in DC. Macrophages and Dendritic
cells were stimulated with 100nM PAF for 16 hours. A. PAFAH expression was
quantified from cell fraction or B. PAFAH activity was quantified in cell free
supernatants. Results are expressed relative to vehicle control and are shown as mean ±
st.dev. **p<0.01.
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3.2.2 c-PAF Suppresses PAFAH Expression in Monocytes, DC and Macrophages

In vivo, PAF is known to be rapidly hydrolyzed by PAFAH. To test the effects of PAF
upon PAFAH expression independent of the effects of PAFAH activity, cells were
treated with methyl carbamyl-PAF (c-PAF), a non-hydrolyzable analog of PAF. PAFAH
expression and activity were significantly suppressed in DC (Figure 17A-B).
Macrophages treated with c-PAF showed a trend towards lower PAFAH expression
compared to vehicle treated cells, however this did not reach statistical significance
(p=0.394). In contrast to PAF, non-hydrolyzable c-PAF did however significantly
suppress macrophage PAFAH activity by approximately 60 percent (Figure 17B). To
further investigate the regulation of PAFAH by PAF upon cells of the monocytic-lineage,
THP1 monocytes were incubated with c-PAF. We observed a similarly dramatic
suppression of PAFAH in the monocyte cell line (Figure 17C).
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Figure 17: c-PAF Suppresses PAFAH Expression in Monocytes, DC and
Macrophages. Macrophages, Dendritic cells and THP1 monocytes were stimulated with
100nM cPAF for 16 hours. A. PAFAH expression was quantified from RNA isolated
from the cell fraction of macrophages or dendritic cells B. PAFAH activity was
quantified in cell free supernatants of macrophages or dendritic cells. C. PAFAH
expression was measured in THP1 monocytes. Results are expressed relative to vehicle
control and are shown as mean ± st.dev. **p<0.01, ***p<0.001.
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3.2.3 c-PAF Suppresses PAFAH Promoter Activity in Monocytes

Stafforini’s group demonstrated that PAF induces PAFAH transcriptional activity in
HEK cells stably transfected with PAF receptor cDNA (Cao et al., 1998d). However, our
data show that PAF suppresses PAFAH expression in DC (Figure 17) and that the PAF
analog c-PAF suppresses PAFAH expression in MO, DC and THP1 monocytic cell line
(Figure 17). To determine whether these effects upon transcriptional activity are cell-type
specific, we obtained the PAFAH-luciferase promoter construct from the Stafforini group
and transfected it into THP1 human monocytes. Transfected THP1 monocytes were
treated with c-PAF and PAFAH transcriptional activity was quantified using a luciferase
activity assay. In contrast to effects reported by the Stafforini group in HEK cells,
PAFAH promoter activity was significantly reduced by c-PAF by approximately 50
percent (Figure 18). These data confirmed our observations regarding the suppressive
effects of PAF and c-PAF and demonstrated that this regulation was at transcriptional
level.
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Figure 18: c-PAF Suppresses PAFAH Promoter Activity in Monocytes. THP1
monocytes transiently transfected with a PAFAH reporter construct were treated with cPAF for 16 hours. PAFAH promoter activity was measured in cell lysates and normalized
to B-galactosidase. Mean ± st.dev of three independent experiments is shown.
***p<0.001.

Experiment performed by Jean Lin
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3.2.4 Basal PAFAH Activity is Low in Dendritic Cells

We were intrigued by the differential responses of macrophages and dendritic cells to
PAF and c-PAF. PAF suppressed PAFAH activity in DC alone, c-PAF significantly
suppressed PAFAH activity in both DC and macrophages (Figures 16-17). While c-PAF
is a non-hydrolyzable analog of PAF, PAF itself is catabolyzed by PAFAH. Previous
studies by our laboratory demonstrated that basal PAFAH is high in macrophages
compared to DC (Al Darmaki et al., 2003). We hypothesized that high levels of PAFAH
activity present in macrophages rapidly hydrolyze PAF. As c-PAF is a non-hydrolyzable
analog, the levels of PAFAH activity present would not affect signaling induced by cPAF. To confirm that our macrophages have similarly high levels of PAFAH to those
previously shown, we quantified basal PAFAH activity and mRNA in macrophages and
DC. Consistent with observations by Al Darmaki et al, we found that macrophages have
approximately 5-fold greater resting levels of PAFAH expression and activity compared
to DC (Figure 19) (Al Darmaki et al., 2003). This suggests that high levels of basal
PAFAH in macrophages might limit the response to PAF.
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Figure 19: Basal PAFAH Is Low in Dendritic Cells. Macrophages and dendritic cells
were incubated overnight in the absence of serum then PAFAH quantified. A. PAFAH
expression was analyzed using qPCR. B. PAFAH activity was measured using
radiometric assay. Data are representative of at least five independent experiments and
are displayed as mean ± st.dev. ***p<0.001.
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3.2.5 POVPC Suppresses PAFAH Expression in THP-1 Monocytes

Short-chain PAF-like oxidized phospholipids have been identified in preparations of
mildly oxidized LDL (Marathe et al., 2001). POVPC, in particular has been shown to
partially signal through the PAF receptor (Pegorier et al., 2005). DC treated with POVPC
show no alteration in PAFAH (Figure 10B). However, while DC possess lower PAFAH
expression than macrophages, they have significantly higher levels than monocytes.
POVPC is a potential target for PAFAH suggesting that DC express ample PAFAH to
hydrolyze POVPC thereby preventing signaling. THP1 monocytes express low levels of
PAFAH. This led to the hypothesis that like PAF, POVPC would suppress PAFAH
expression in THP1 monocytes. To test this hypothesis we treated THP1 monocytes with
POVPC and quantified PAFAH expression by qPCR. The exceptionally low levels of
PAFAH activity present in THP1 monocytes did not allow the quantification of
enzymatic activity. POVPC dose-dependently suppresses PAFAH with approximately
ninety percent suppression at 50µM (Figure 20). The data in Figure 20 represents a single
experiment. Reproducibility proved difficult when stimulating THP1 monocytes with
POVPC. Perhaps because the basal expression of PAFAH in these cells is close to the
lower limit of detection. In some experiments THP1 monocytes were sensitive to POVPC
and underwent cell death. Our data suggest that POVPC may suppress PAFAH
expression but further experimentation must be conducted for conclusive evidence.
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Figure 20: POVPC Suppresses PAFAH Expression in THP1 Monocytes. THP1
monocytes were stimulated with 0, 5, 10, 25 or 50µM POVPC for 16 hours. PAFAH
expression is normalized to 18S expression. Results are from a single experiment
conducted in triplicate. Mean ± StDev are shown. ** p<0.01.
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3.2.6 PAFAH Expression is Altered by Lyso-PAF

PAFAH hydrolysis of PAF leads to the formation of lyso-PAF and acetate. To determine
whether the products of PAFAH action have any effects upon expression of the enzyme,
we treated DC and macrophages with lyso-PAF. In a single experiment, dendritic cells
and macrophages treated with 100nM lyso-PAF responded in a differential manner.
Lyso-PAF induced PAFAH expression significantly in macrophages but not DC (Figure
21). These data are from a single experiment. Upon a second occasion, these observations
were not repeated, and no change in PAFAH expression was observed (data not shown).
Further investigation is warranted to determine the effects of lyso-PAF upon PAFAH
expression.
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Figure 21: PAFAH Expression is Altered by Lyso-PAF. Macrophages and Dendritic
cells were treated with 100nM lyso-PAF for 16 hours. PAFAH expression was quantified
by qPCR. Data shown represent a single experiment where the relative level of PAFAH
expression is shown relative to vehicle control. *p<0.05.
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3.4 Discussion
PAF and the enzyme that inactivates it, PAFAH, are linked to a variety of inflammatory
diseases (Zimmerman et al., 2002). Several researchers have investigated the regulation
of PAFAH but there is a general lack of consistency in results that may be a direct
consequence of the models used. Our study focused upon the use of the physiologically
relevant monocytic cell model. We demonstrate that PAF suppresses PAFAH expression
and this is reflected in an associated decrease in enzyme activity (Figure 16). PAFAH
expression increases dramatically as monocytes differentiate (Elstad et al., 1989) and
furthermore PAFAH expression is significantly higher in macrophages versus DC (Al
Darmaki et al., 2003). High levels of PAFAH activity would result in more rapid
catabolism of its substrates. The hydrolysis of PAF in macrophages likely plays an
important role in the blunting of the suppressive signaling. Use of the non-hydrolyzable
compound c-PAF allowed us to effectively inhibit PAFAH by making the relative
PAFAH activity redundant. C-PAF suppressed macrophage PAFAH expression in a
manner comparable to DC and THP1 monocytes (Figure 17). This suggests that the basal
level of PAFAH activity possessed by the cell limits the overall effect of PAF upon
PAFAH expression. Our study is the first to demonstrate the regulation of PAFAH by
PAF in a physiologically relevant cell model. This may have important consequences for
our understanding of the regulation of PAFAH in inflammatory conditions.

Al-Darmaki et al, showed that PAF accumulation is higher in DC than in macrophages
(Al Darmaki et al., 2003). The same group also demonstrated that PAF-induced PGE2
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release is higher in DC than in macrophages and that this is likely a direct consequence of
low DC PAFAH activity and consequent longer half-life of PAF in DC (Al Darmaki et
al., 2003). Our study reveals an additional consequence of the relative level of PAFAH
activity. In cells with low basal PAFAH, PAF is able to lower PAFAH expression further
which may allow inflammation to persist. For example, patients with neonatal necrotizing
enterocolitis (NE) have elevated PAF levels while plasma PAFAH is decreased (Hsueh et
al., 2003). Additionally, a similar pattern of significantly higher plasma PAF and lower
PAFAH activity is measured in subjects with Hepatitis C Virus (HCV) (Caini et al.,
2007). Our data suggests that the induction of PAF is responsible for significantly lower
PAFAH expression and activity in patients with NE and HCV. In HEK cells, PAF
induced PAFAH transcription (Cao et al., 1998d) suggesting a negative feedback loop for
the inactivation of PAF. Our study reveals that in the physiologically relevant model of
monocytes and monocyte-derived cells, PAF suppresses PAFAH. This in vitro
phenomenon is supported by the observations in human inflammatory diseases such as
NE and HCV. This suggests that the continued formation of PAF leads to a prolonged
suppression of PAFAH. This allows the persistence of PAF and hence chronic
inflammation ensues.

The recruitment of immature DC to inflammatory sites is a critical component of the
inflammatory response. Many factors have been shown to induce this recruitment
including PAF, chemokines and sphingosine 1-phosphate (S1P) (Dichmann et al.,
2000;Idzko et al., 2002;Sozzani et al., 2000). The PAF receptor is present in immature
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DC however its expression is lost upon their maturation (Dichmann et al., 2000)
reinforcing the role of PAF in the immature DC. During maturation DC acquire the
ability to migrate to secondary lymphoid tissues where they prime T-cells. PAF is not
required for the migration of mature DC as evidenced by the loss of PAF receptor
expression (Dichmann et al., 2000). We propose that PAF-mediated suppression of
PAFAH is required to maintain elevated levels of PAF for the continued influx of
immature DC to the site of inflammation and therefore the progression of the
inflammatory response.

PAF is not the sole bioactive phospholipid that has been suggested to signal through the
PAF-R. During atherosclerosis, short-chain oxidized and fragmented phospholipids are
generated upon the oxLDL particles that have also been proposed to bind the PAFreceptor (Pegorier et al., 2005). Marathe et al showed oxLDL to contain PAF-like lipids
(Marathe et al., 2001). oxLDL stimulates activation of the PAF-R in monocytes and
down-regulation of LPS-induced PAF-R expression in monocyte-derived macrophages
(Beaudeux et al., 2004a;Hourton et al., 2001). Lehr et al showed administration of
oxLDL in vivo, promoted leukocyte adhesion to endothelium and this was inhibited by
the PAF-R antagonist WEB2170 (Lehr et al., 1993a). If such short-chain PAF-like lipids
are capable of signaling through the PAF-receptor, it is likely that they will then also
suppress PAFAH expression in DC. Our preliminary data (Figure 10B) suggest that DC
do not respond to 10uM POVPC and a modest induction of PAFAH is observed in
response to PGPC. In THP1 monocytes, early experiments showed that POVPC could
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dose-dependently suppress PAFAH expression (Figure 20) however additional
experiments revealed that even moderate doses of POVPC, but not PGPC potently kills
cells. We are intrigued by the sensitivity of monocytes to POVPC and further studies will
investigate whether lower doses modulate PAFAH expression.

In summary, we have demonstrated that PAF suppresses PAFAH expression. The relative
level of PAFAH activity present in the cell affects this. We also show that the PAF-like
oxPL, POVPC may also suppress PAFAH expression although further investigation is
warranted to confirm our preliminary results. The suppression of PAFAH may have
important implications for the development of the immune response and atherosclerosis.
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CHAPTER IV: THE REGULATION OF PLATELET ACTIVATING FACTOR
ACETYLHYDROLASE IN PERIODONTITIS

4.1 INTRODUCTION

Periodontitis is an inflammatory disease of the oral cavity that is bacterial in origin
(Grossi et al., 1994;Grossi et al., 1995). Gram-negative bacteria such as Actinobacillus
actinomycetemcomitans and Porphyromonas gingivalis infiltrate the gingival tissue to
initiate an inflammatory response that is the main destructive component of the disease.
Periodontitis may be classified by the age of onset as well as by the affected areas.
Aggressive forms of the disease usually develop in young adults and cause significant
bone destruction and attachment loss. Localized aggressive periodontitis (LAgP) affects
usually only first molars and incisors and Generalized Aggressive periodontitis (GAgP)
has a widespread pattern specifically affecting a larger number of teeth (Gustke,
1998a;Gustke, 1998b). These aggressive forms of periodontitis are rare and their
occurrence is influenced heavily by genetics and race. Adult onset periodontitis is known
as chronic periodontitis and generally begins beyond age 35. The disease is characterized
by progressive loss of alveolar bone and soft tissue but is not as aggressive as the early
onset forms.
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Accumulating evidence suggests an elevated risk of cardiovascular disease development
in periodontitis patients. These diseases share common risk factors such as age, diabetes
mellitus, obesity, smoking and infection (Pischon et al., 2007;Schenkein et al., 1995).
Largely, the evidence points toward chronic periodontitis patients as being at risk of
developing CVD. However, there are also data suggesting that AgP subjects may be at
risk for CVD. For example, GAgP subjects have elevated pro-atherogenic small dense
LDL in their plasma (Rufail et al., 2005). Schenkein, Tew and others have shown that
AgP patients, like CP subjects have elevated anti-cardiolipin protein compared to nonperiodontitis (NP) subjects (Schenkein et al., 2003a;Schenkein et al., 2007) (Salzberg et
al., 2006). Patients with periodontal disease also have higher concentrations of IgG antiPC and anti-CL that is cross reactive with oral bacterial antigens and human antigens
including oxLDL (Schenkein et al., 1999). The gingival crevicular fluid of periodontitis
patients also contains anti-PC and anti-oxLDL (Schenkein et al., 2004). Infection with
P.gingivalis has been demonstrated to exacerbate atherosclerosis in ApoE-deficient mice
(Lalla et al., 2003). While Grau et al have shown that periodontal disease is a risk factor
for ischemic stroke (Grau et al., 2004b). Odds ratios for periodontitis and atherosclerosis
vary from 0.79 to 2.68. Clinical treatment of periodontitis significantly reduces PAF
levels in the crevicular fluid and improves periodontitis suggesting that PAF is an
important inflammatory mediator in this disease (Rasch et al., 1995). Altogether these
data are suggestive that AgP is connected to atherosclerosis. Further studies are
warranted to investigate the full extent of the relationship between these two diseases.
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Monocytes from subjects with LAgP have a greater tendency to differentiate into DC
than their NP counterparts (Barbour et al., 2002c). Our data demonstrate that DC are
hyperresponsive to long-chain oxPL and PAF, compared to macrophages. These facts led
us to hypothesize that AgP monocytes are hyperresponsive to oxPL and PAF owing to
their propensity to differentiate into DC, and this may have consequences in
atherosclerosis. Given the strong association of PAFAH in atherosclerosis any alteration
in the expression of this enzyme could have an adverse outcome on the progression of the
disease. Therefore we investigated the regulation of PAFAH by oxPL and PAF in
periodontitis.
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4.2 MATERIALS AND METHODS

4.2.1 Materials
OxPAPC and its fractions were prepared as described previously (Birukov et al., 2004c)).
M-CSF, GM-CSF and IL-4 were all from RnD Systems (Minneapolis, MN). [3H-]PAF
was purchased from New England Nuclear/PerkinElmer (Boston, MA). 1-alkyl-2-acetylsn-glycero-3-phosphocholine
phosphocholine

were

(PAF)

purchased

and

1-palmitoyl-2-arachidonyl-sn-glycero-3-

from Avanti Polar Lipids (Alabaster, AL).

Lipopolysaccharide (LPS) and Fetal Calf Serum were purchased from Sigma (St Louis,
MO). Human Serum was from Cambrex (Walkersville, MD). Lymphocyte separation
medium was from MP Biomedicals (Solon, OH). RT-PCR primers were purchased from
Integrated DNA Technology (Coralville, IA).

4.2.2 Human Subjects
Subjects were recruited, and periodontal health was assessed by the Clinical Research
Center for Periodontal Diseases (CRCPD), Virginia Commonwealth University.
Individuals studied were non-smoking males and females. Clinical classification of
disease is outlines in Table 6.
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Periodontal Status

Guidelines

Non-Periodontitis (NP)

No evidence of attachment loss at more than one site, or
pockets greater than 3mm. Gingival inflammation may be
present. Age- and race-matched with periodontitis
subjects

Localized Aggressive

At least 4 mm attachment loss (AL) on at least 2

Periodontitis (LAgP)

permanent first molars and incisors (at least one molar
must be affected) and no more than 2 teeth, which are not
first molars or incisors, affected by 5 mm AL or more.
Subjects have evidence of disease onset from puberty to
age 35 and of rapidly progressive loss of attachment

Generalized Aggressive

At least 8 teeth affected (5mm AL or more), at least 3 of

Periodontitis (GAgP)

which are not first molars and incisors. Subjects have
evidence of disease onset from puberty to age 35 and of
rapidly progressive loss of attachment

Table 6: Guidelines of Periodontal Status Applied to Subjects Within this Study
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4.2.3 Primary Cell Culture and Differentiation
Approximately 40ml of Buffy coat was diluted with 40ml RPMI. Diluted buffy coat was
layered on a ficoll gradient then centrifuged for 30 minutes at 300g at 20C. The
mononuclear layer was washed three times with RPMI and centrifugation at 1500g for 10
minute washes. Each time the supernatant was removed and the pellet washed again.
After three washes the pellet was resuspended in RPMI supplemented with 10% Human
AB Serum. Cells were plated at a density of 107 per well in 6 well plates and incubated
for 1-2 hours at standard cell culture conditions. Supernatant and non-adherent cells were
removed and monolayer was washed 3 times with plain RPMI. Monocytes were treated
in serum-free media at this point. Other monocytes were induced to differentiate with
cytokine for 7 days into DC with 800U/ml GM-CSF and 500U/ml IL-4 in RPMI with
10% Fetal Calf Serum or into Macrophages with 1000U/ml M-CSF in RPMI with 10%
Human Serum. Macrophage and Dendritic cell RPMI media was also supplemented with
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. FACS analysis was
previously used to confirm that differentiation conditions were successful (Al Darmaki et
al., 2003).

4.2.4 Isolation of Low-Density Lipoprotein
Human peripheral blood was drawn after an overnight fast and collected in five, 10ml BD
vacutainers with K3 EDTA. Blood was divided equally into two centrifuge tubes and
centrifuged at 3,000g for 20min at 4°C. Plasma was collected after this first
centrifugation and was supplemented with 500ul Protease I inhibitor NaN3 (0.02%) and
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EDTA (1mM). Plasma was mixed with stock density solution then transferred to two
centrifuge tubes. An overlay of stock density solution was added to the tube. Samples
were centrifuged at 45,000rpm at 20°C for 20 hours. After the first centrifugation, the
upper cloudy layer of VLDL was removed. The infranatant density was checked using a
refractometer to ensure it was between 1.015 and 1.017. Once this certain, the remaining
infranatant was removed and the pellet resuspended. Stock density solution was added
and the overlay added over the top. Samples were centrifuged for a further 45,000rpm at
20°C for another 20 hours. At the end of this time, the upper cloudy layer of LDL was
removed from the tubes. Density of infranatant was checked as 1.063 then LDL stored
under argon/nitrogen at 4°C until use.

4.2.5 Protein Assay of Low Density Lipoprotein
Protein concentration was determined using a modified Lowry method with a BSA
standard (Miwa et al., 1988). Reagent A was made with 20ml CTC reagent, 40ml 5%
SDS solution and 20ml 0.8M NaOH. Reagent B was Folin Reagent diluted 1:6 with H20.
Dialyzed LDL or BSA were incubated with 0.5ml Reagent A for 10 minutes at room
temperature. Then 0.25ml Reagent B was added, mixed and incubated at room
temperature for 30 minutes. At this point absorbance was measured in a
spectrophotometer at 750nm against blank.
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4.2.6 Oxidation of Low Density Lipoprotein
LDL was dialyzed before oxidation or before incubation with cell cultures using dialysis
membrane in phosphate buffered saline. Stir bar present over night in cold room. LDL
Oxidation LDL was preserved in its native form (nLDL) or oxidized by 2.5μM CuS04 as
described previously (Anthonsen et al., 2000a) to produce oxidized LDL (oxLDL). LDL
preparations were supplemented with NaN3 and EDTA post-oxidation to preserve and
protect against further modification. Conjugated dienes were determined by
spectrophotometric analysis of 50µg/ml LDL preparations at 234nm (nLDL<0.2,
oxLDL=0.4). LDL was extensively dialyzed against PBS before incubating with cells.
Cell cultures were treated with 50μg/ml LDL for 16 hours.

4.2.7 Platelet Activating Factor Acetylhydrolase Activity Assays: Substrate consisted
of 50µM 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine with 0.05 µCi of hexadecyl-2acetyl-sn-glyceryl-3-phosphocholine,

1-O-[acetyl-(N)-3H]

(NEN/PerkinElmer;

13.5

Ci/mmol) added as a tracer. Substrate was incubated with conditioned medium (enzyme
source) and incubated for 30 minutes at 37°C. PAFAH activity was determined as release
of [3H] acetate as quantified by scintillation counting.

4.2.8 RNA Isolation and Platelet Activating Factor Acetylhydrolase Quantitative
Real-Time PCR
RNA was isolated with the Trizol reagent (Invitrogen). PAFAH specific primers were
used to amplify product and normalized to 18S RNA (Table 7). PAFAH and 18S mRNA
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was measured by quantitative real time PCR (qPCR). Primer and Probe Sequences are
shown in Table 6. Real time PCR reactions were performed with the TaqMan® One-Step
kit from ABI on an ICycler instrument from BioRad.

4.2.9 Statistical Analyses
Data are presented as mean +/- standard deviation. Student t-tests, ANOVA or MannWhitney non-parametric analyses were performed and statistical significance is expressed
as *P<0.05, **P<0.01, ***P<0.001.
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PAFAH

18S

Sense
AntiSense
Probe
Sense
AntiSense
Probe

5’tgcgtttatattatccatcccaa-3’
5’agttgtcattgcaccaaagagt-3’
5’atgatcgccttgacaccctttgga3’
5’aaaattagagtgttcaaagcaggc3’
5’cctcagttccgaaaaccaacaa3’
5’cgagccgcctggataccgcagc3’

Table 7: PAFAH and 18S Primer and Probe Sequences
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4.3 RESULTS

4.3.1 Aggressive Periodontitis Monocytes Spontaneously Differentiate Into DC

Of the two aggressive forms of periodontitis, GAgP is the more severe. LAgP subjects’
monocytes have a propensity to differentiate into DC (Barbour et al., 2002b). We
hypothesized that GAgP monocytes would also differentiate towards a DC phenotype
rather than the predominantly macrophage population observed with non-periodontitis
(NP) monocytes. To test this, monocytes isolated from NP and GAgP monocytes were
allowed to spontaneously differentiate for seven days before morphology was observed.
As shown in Figure 22, GAgP monocytes displayed a typically DC phenotype compared
to NP monocytes. In this study we did not further investigate the phenotype or function of
DC-like cells. These experiments will be conducted in the future to confirm that GAgP
monocytes spontaneously differentiate into DC. However, the morphology of these cells
suggests GAgP monocytes do indeed become DC, as previous studies have shown is the
case with LAgP monocytes (Barbour et al., 2002a)
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Non-Periodontitis Monocytes

Generalized Aggressive Periodontitis Monocytes

Figure 22: Generalized Aggressive Periodontitis Monocytes Spontaneously
Differentiate Into DC. Adherent monocytes isolated from NP or GAgP patients were
cultured for 7 days in human serum. Photomicrographs of the cultures were taken and
morphology studied. Arrows indicate the presence of cells with dendritic cell-like
morphology.

The

results

of

a

representative
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experiment

are

shown

(n=3).

4.3.2 Basal PAFAH Is Low in Monocytes from Generalized Aggressive Periodontitis
Subjects

Maturation of monocytes into DC and macrophages is associated with a significant
increase in PAFAH expression (Al Darmaki et al., 2003;Elstad et al., 1989).
Macrophages especially have high levels of PAFAH that are 5-fold or greater than DC
(Figure 19). Similarly, differentiated NP monocytes have significantly elevated levels of
PAFAH compared to LAgP monocytes (Barbour et al., 2002c). We theorized that GAgP
monocytes that are more likely to differentiate into DC have similarly low levels of basal
PAFAH. To test this, relative PAFAH expression was quantified by qPCR (Figure 23).
ANOVA statistical analyses revealed a probability value of p=0.009 between the groups.
(F= 6.516) indicating that there is a low probability that these differences exist by random
occurrence. Enzymatic activity assays confirmed that GAgP monocytes have
significantly lower levels of PAFAH than NP monocytes (Figure 23B). We therefore
conclude that GAgP monocytes have significantly lower basal PAFAH expression than
NP monocytes.
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Figure 2: Basal PAFAH Is Low in Periodontitis Monocytes
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Figure 23: Basal PAFAH Expression and Activity are Low in AgP Monocytes
Macrophages and dendritic cells were incubated overnight in the absence of serum then
PAFAH quantified. A. PAFAH expression was analyzed using qPCR. B. PAFAH activity
was measured using radiometric assay. Data are representative of at least five
independent experiments and are displayed as mean ± st.dev. *p<0.05.
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4.3.3 PAF Suppresses PAFAH in GAgP but Not NP Monocytes

We have demonstrated that PAF suppresses PAFAH expression in DC but not
macrophages (Figure 16). GAgP monocytes look like DC and express low levels of basal
PAFAH like DC. To determine whether these cells also respond in a manner analogous to
that of DC, cells were treated with 100nM PAF for 16 hours. While NP monocytes did
not respond to PAF, the levels of PAFAH in GAgP monocytes were significantly reduced
by approximately 50% (Figure 24). Treatment of GAgP monocytes with the nonhydrolyzable PAF analog c-PAF similarly reduced PAFAH expression (Figure 24).
PAFAH was significantly suppressed in NP monocytes treated with c-PAF (Figure 24).
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NP
GAgP

Figure 24: PAF Suppresses PAFAH Expression in GAgP Monocytes. Differentiated
NP and GAgP monocytes were treated for 16 hours with 100nM PAF or c-PAF. PAFAH
expression was quantified and normalized to 18S. Data are expressed as relative to
vehicle control. NP are shown as open bars while GAgP monocytes are represented by
grey bars. Data shown are from six independent patients that were age- and racematched. Mean ± st.dev. are shown.
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4.3.4 Oxidized LDL Induces PAFAH in AgP Monocytes

OxLDL is proatherogenic, signaling many events that lead to atherosclerosis
development (Frostegard et al., 1990). Oxidized phospholipids in oxLDL are proposed to
be targets for PAFAH (Foulks et al., 2009;Marathe et al., 2002). AgP monocytes
differentiate into DC and possess low levels of PAFAH (Figures 22 and 23).
Additionally, AgP monocytes respond to PAF and c-PAF in a manner analogous to that
of DC (Figure 24). We hypothesized that AgP monocytes would respond to oxLDL like
DC and PAFAH expression would be induced. To test this NP and AgP monocytes were
stimulated with a mildly oxidized LDL species that is known to induce PAFAH
expression in DC (Figure 14). Cells were treated overnight before PAFAH expression
was analyzed by qPCR. NP monocytes were unresponsive to oxLDL with a mean fold
induction of 0.86 in 11 samples. AgP monocytes, like DC were responsive to oxLDL
with a mean induction of 3.34-fold (n=15). Statistical analyses revealed that the oxLDLmediated induction of PAFAH is significantly higher in AgP monocytes (p=0.0006).
LAgP (n=4) and GAgP monocytes (n=11) were grouped together in this study. We
observed that LAgP monocytes were particularly sensitive to oxLDL although additional
subjects are required to fully investigate any differences between the GAgP and LAgP
groups.

129

14
NP

Fold PAFAH Expression

12

AgP

10

8

6

4

2

0
NP

AgP

Figure 25: oxLDL Induces PAFAH in AgP Monocytes. Differentiated NP, and AgP
monocytes were treated with 50µg/ml Mildly Oxidized LDL for 16 hours. PAFAH
expression was quantified, normalized to 18S and is expressed as relative to vehicle
control for each subject. Datapoints represent fold PAFAH induction for individual
subjects in each group. NP subjects n= 11; AgP subjects n=15.
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4.3.5 Oxidized Phospholipids Induce PAFAH Expression in GAgP Monocytes

DC play an important role in inflammation and are emerging as key components in the
development of the atherosclerotic plaque (Bobryshev, 2000e;Bobryshev, 2005).
Oxidized Phospholipids are produced during atherosclerosis and mediate a variety of proatherogenic events (Leitinger, 2003). These are significant bioactive components of
oxLDL and we have shown that DC, but not MO are sensitive to oxPAPC, responding
with a robust induction in the expression of PAFAH (Figure 9). Preliminary data with a
relatively small number of subjects (n=1 NP; n=3 GAgP) indicates that GAgP monocytes
that spontaneously differentiate into DC are also responsive to oxPAPC. With monocytes
isolated from three subjects, oxPAPC stimulated PAFAH between two- and twelve-fold.
Our preliminary observations suggest that the predominantly macrophage-like NP
monocytes are unresponsive to oxPAPC. However, thus far monocytes from a single
patient were stimulated with 50µg/ml oxPAPC. Additional NP and GAgP subjects will be
analyzed to confirm these preliminary results.

131

4.4 DISCUSSION

Our data show that like LAgP monocytes, GAgP monocytes express basal PAFAH at low
levels (Al Darmaki et al., 2003) (Figure 23). This may have important consequences for
inflammation in the context of the periodontal health of these subjects. Specifically, low
PAFAH activity allows the persistence of pro-inflammatory PAF thus permitting chronic
inflammation to ensue. GAgP is a particularly chronic type of aggressive periodontitis
with attachment loss widespread through the oral cavity. PAF is known to accumulate in
the gingival crevicular fluid of GAgP subjects and removal of this lipid eases symptoms
of the disease (Rasch et al., 1995). We show that PAF suppresses PAFAH expression in
GAgP monocytes (Figure 24). This suggests that an accumulation of PAF in AgP
subjects would reinforce the inflammatory response by suppressing PAFAH. The nonhydrolyzable PAF analog c-PAF reduces PAFAH expression in both NP and GAgP
monocytes. This suggests that NP subjects that possess high PAFAH activity are wellequipped to catabolyze pro-inflammatory PAF. However, GAgP subjects have a greater
propensity to differentiate into DC with low PAFAH and PAF signaling persists. That is
not to say that this is the sole factor in the persistence of PAF and for the disease itself.
There are many factors at play including a genetic predisposition but the relative
contribution of PAF, PAFAH and the DC is certainly a factor in this disease.

In addition to the disadvantages of low or suppressed PAFAH expression in periodontitis,
there may be important implications in atherosclerosis. PAF and oxPL contained upon
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the oxLDL particle are involved in the pathogenesis of atherosclerosis (Marathe et al.,
2002). Pro-inflammatory oxLDL and oxPAPC potently stimulate PAFAH expression and
activity in GAgP monocytes (Figures 25 and data not shown) but not NP monocytes.
These observations are comparable to our observations in DC and macrophages (Figures
9 and 14). Our research indicates that long-chain, but not short-chain oxPL are
responsible for the induction of PAFAH in DC (Figure 10). It is therefore plausible that
the same components of oxPAPC and oxLDL induce PAFAH expression in DC-like AgP
monocytes. The role of PAFAH in atherosclerosis has been controversial although
overwhelming data now suggest this enzyme is pro-atherogenic (Packard et al.,
2000b;Yamada et al., 2000b;Zalewski and Macphee, 2005a). GAgP monocyte
differentiation is skewed towards a DC phenotype and these cells are sensitive to proatherogenic stimuli (PAF and oxPAPC). The accumulation of DC in the atheroma
combined with their PAFAH- and inflammatory cytokine-producing potential suggests a
potential source of the susceptibility of periodontitis patients to atherosclerosis. To date
the major epidemiological studies regarding periodontitis and atherosclerosis show
modest odds ratios from 0.79 to 2.68. Moreover, these studies were conducted using
subjects with chronic periodontitis and not those with AgP. Future studies by our group
will focus upon the responses of CP monocytes to PAF, oxLDL and oxPL and compare
these observations to those in AgP monocytes.

In the DC and MO model (Chapter II), the low levels of IL-6 receptor upon the MO is the
likely cause of the unresponsiveness of these cells to oxLDL. We have yet to fully133

investigate the expression of IL-6 receptor upon NP and GAgP monocytes. It is possible
that spontaneously differentiated GAgP monocytes that look like DC express higher
levels of IL-6 receptor than do the macrophage-like NP monocytes. Given the similarity
of the cells and their comparable responses this seems likely. However we cannot rule out
the possibility that another underlying cause exists. For example AgP monocytes are
known to produce elevated levels of IL-6 (Sun et al., 2009). IL-6 is elevated in
atherosclerosis and periodontal disease (Ioannidou et al., 2006;Schieffer et al.,
2004;Shapira et al., 1994). Furthermore, apoE mice infected with the periodontitisassociated pathogen P.gingivalis have accelerated atherosclerosis in comparison to
uninfected apoE mice (Lalla et al., 2003). This is accompanied by increased plasma IL-6
production in infected mice. It is possible that activated AgP monocytes have an
increased potential to make IL-6 and that this contributes to their sensitivity to oxLDL
and oxPAPC.

While short-chain oxPL are proposed targets for PAFAH, long-chain oxPL are much less
likely substrates for PAFAH given their sn-2 acyl chain length. However, recent studies
suggest that these unlikely substrates are indeed targets of PAFAH although they are not
as good substrates as the short-chain oxPL (Davis et al., 2008). If long-chain oxPL are
indeed PAFAH substrates the high levels of PAFAH activity present in NP monocytes
and macrophages is a potential additional explanation for their lack of response to longchain fractions of oxPAPC.
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Overall our data reveal that like LAgP monocytes (Al Darmaki et al., 2003) GAgP
monocytes have a propensity to differentiate into DC-like cells. These spontaneously
differentiated monocytes express significantly lower basal levels of PAFAH than NP
subjects’ monocytes. Additionally they respond like cytokine-differentiated DC to PAF,
c-PAF, oxPAPC and oxLDL. This confirms the utility of cytokine-differentiated DC and
macrophages as models for in vivo-differentiated DC and macrophages. The low PAFAH
expression of GAgP monocytes as well as their propensity to differentiate into DC
emphasizes the skewed lipid metabolism associated with the disease. In addition to low
monocyte PAFAH expression, GAgP subjects have low LDL-associated PAFAH activity
(Rufail et al., 2005). GAgP subjects also possess greater numbers of circulating LDL
particles and these particles are smaller suggesting an increased prevalence of
proatherogenic small-dense LDL (Rufail et al., 2005). Whether pro- or anti-inflammatory
in the context of atherosclerosis, it is clear that PAFAH has a key role in development of
this disease and further investigations into the regulation of this enzyme are warranted.
The potential causes of the differential responses of AgP and NP monocytes to oxLDL
and oxPAPC will be more thoroughly investigated in the future.
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CHAPTER V: GENERAL DISCUSSION

Despite its role in inflammation, the regulation of PAFAH is not well characterized. First
identified as an enzyme involved in the regulation of the inflammatory response, PAFAH
was considered to be protective. Since its discovery PAFAH has been linked with a
variety of inflammatory diseases including periodontitis and type I diabetes (Elter et al.,
2003a;Gomes et al., 2008), retaining its protective status. More recently PAFAH has been
connected with atherosclerosis. Controversy has surrounded the role of PAFAH in
atherosclerosis however accumulating evidence suggests that PAFAH contributes to the
progression of the disease (Ballantyne et al., 2005b;Wilensky et al., 2008). What is
certain is that our limited understanding of the regulation of PAFAH prevents resolution
of this issue. To elucidate the signals that regulate PAFAH will certainly increase our
understanding of the role that this enzyme plays in atherosclerosis and inflammation in
general. Furthermore, the study of PAFAH regulation will potentially lead to the
generation of therapeutic targets for PAFAH itself or against regulators of this enzyme.
This study addressed the potential for the regulation of PAFAH by its bioactive
phospholipid targets.

One of the major findings of this study is the differential responses that macrophages and
DC make to PAF and oxPL. Other studies have demonstrated the differential regulation
of PAFAH in macrophages and DC (Al Darmaki et al., 2003). Our research further
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establishes the disparate responses of macrophages and DC to oxPL and PAF. The
relative abundance of PAFAH in macrophages is almost certainly a critical factor in the
lack of response to PAF. This is illustrated by the sensitivity of macrophages to the nonhydrolyzable PAF analog c-PAF. Our data also reveal that like LAgP monocytes, GAgP
monocytes spontaneously differentiate into DC and respond like DC to PAF and oxLDL
(Al Darmaki et al., 2003;Barbour et al., 2002c)(Figures 22-23). Previous reports showed
that PAF induced the expression of PAFAH (Cao et al., 1998d) however we show that
PAF suppresses PAFAH expression (Figure 24). This phenomenon would allow the
persistence of PAF and therefore its inflammatory effects.

PAF has long been associated with periodontitis. It is present in gingival crevicular fluid
(Emingil et al., 2001) and correlates with disease severity (Garito et al., 1995). PAF
accumulation has also been linked with necrotizing enterocolitis, Hepatitis C Virus,
anaphylaxis and bronchial asthma (Caini et al., 2007;Hsueh et al., 2003;Tsukioka et al.,
1996;Vadas et al., 2008). In all of these diseases, elevated PAF is inversely associated
with PAFAH. Our data reinforce the idea that PAF suppresses PAFAH during
inflammation and that continued PAFAH suppression contributes to the inflammatory
component of these diseases. Ultimately, in a chronic disease such as periodontitis where
PAF is persistent, the prolonged suppression of PAFAH may result in chronic
inflammation.
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The recruitment of immature DC to the site of inflammation is mediated by PAF
(Dichmann et al., 2000). As DC mature, expression of the PAF receptor is lost
(Dichmann et al., 2000). During maturation, DC gain the ability to migrate to the lymph
to activate T cells and promote the resolution of inflammation. PAF and PAF-like oxPL
sequester DC at the site of inflammation (Angeli et al., 2004c). Migration is improved
following treatment with the PAF receptor antagonist CV3988. The most dramatic
restoration of DC migration was observed in PAF receptor knockout mice that showed
two-fold greater emigration than their wild-type counterparts (Angeli et al., 2004c).
These observations suggest that PAF prevents the migration of DC to the lymph. DC
produce potent inflammatory cytokines and therefore the trapping of these cells at the site
of inflammation would lead to the aggravation of the local immune response.

PAF-like oxPL such as POVPC are generated during oxLDL generation (Marathe et al.,
2001). These short-chain oxPL may bind the PAF receptor to mimic PAF signaling such
as inducing the adhesion of leukocytes to the endothelium (Lehr et al., 1993c;Pegorier et
al., 2005). Our studies with PAF predict that these PAF-like oxPL would suppress
PAFAH expression. Our preliminary data in THP1 monocytes indicate that POVPC may
also suppress PAFAH expression (Figure 20). Surprisingly DC were unresponsive to
POVPC suggesting a) that the sensitivity of DC is different to that of THP1 monocytes or
b) that the mechanism for PAFAH suppression is not solely mediated by the PAF
receptor. Importantly further experiments in THP1 monocytes treated with POVPC
revealed that these cells are sensitive to POVPC. Moderate doses of POVPC, but not
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PGPC led to cell death. There is evidence that POVPC induces apoptosis but at much
greater concentrations than those used in this study. POVPC activates acid
sphingomyelinase to promote apoptosis in smooth muscle cells (Fruhwirth et al.,
2006;Loidl et al., 2003). Increased activity of the enzyme sphingomyelinase converts
sphingomyelin to ceramide, a potent mediator of apoptosis. Apoptosis of smooth muscle
cells and monocytes may contribute to the instability of the plaque and therefore plaque
rupture and breakdown. Hydrolysis of POVPC by PAFAH may therefore be protective in
this instance, although high concentrations of LPC may themselves be apoptotic. The
PAFAH inhibitor Darapladib prevents expansion of the necrotic core (Mohler, III et al.,
2008). This suggests that a decrease in the products of PAFAH activity protect the
atheroma. As high concentrations of LPC induce cell death and likely contribute to the
necrotic core this suggests that the outcome of PAFAH activity is the development and
instability of the atheroma. The sensitivity to POVPC and cell death resulting from
treatment with this oxPL should be further evaluated. We are intrigued by the sensitivity
of monocytes to POVPC and further studies will investigate whether lower doses regulate
PAFAH expression.

Long-chain oxPL are unlikely targets for PAFAH given their sn-2 acyl chain length.
However, a recent study demonstrated that a class of long-chain oxPL that lie within the
range of PEIPC are abundant in oxLDL are PAFAH substrates (Davis et al., 2008). It is
important to note that this study also admitted that long-chain oxPL are not as efficient
substrates as short-chain oxPL (Davis et al., 2008). PEIPC is the best characterized and
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perhaps most bioactive of the long-chain fraction of oxPAPC. It is well established that
oxidation of the sn-2 acyl chain partially offsets the loss of preference for longer chain
length (Stremler et al., 1989b;Stremler et al., 1991). Given this information it is possible
that MO and differentiated NP monocytes hydrolyze long-chain oxPAPC. PAFAH is
significantly elevated in these cells and it is possible that the high activity, combined with
a deficiency of IL-6R is sufficient to eradicate any of the signaling effects that we
observe in DC, monocytes and differentiated AgP monocytes. An important extension of
our results will be to utilize pharmacological inhibitors of PAFAH to determine the
relative impact of the enzyme upon the macrophages. If PAFAH is catabolyzing the longchain oxPL over the incubation period we will expect to see an induction, although
perhaps modest in macrophage PAFAH expression. Additionally, the use of PAFAH
inhibitors such as Pefabloc or Darapladib in DC would perhaps suppress PAFAH activity
allowing an even more prolific response. Low DC PAFAH activity may not be such an
important factor in oxPAPC-induced PAFAH expression. In support of this argument is
the monocyte, with extremely low levels of PAFAH, the monocyte responds no better to
DC to oxPAPC.

Berliner’s group was the first to show that pure PEIPC binds the prostaglandin receptor
subtypes DP1 and EP2 (Li et al., 2006f). These studies were conducted in endothelial
cells that express EP2 alone (Li et al., 2006g). To our knowledge, our study is the first to
investigate signaling of oxPAPC through both DP1 and EP2. We show that PEIPCcontaining long-chain fractions of oxPAPC induce PAFAH expression in DC and
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monocytes (Figure 10). The potential for oxPL binding a G-protein coupled receptor was
first demonstrated by the activation of endothelial cell cAMP by minimally modified
LDL (Parhami et al., 1993). More recently PEIPC was shown to bind DP1 and EP2, both
of which are coupled to Gsα subunits (Liu et al., 2002a). Activation of both receptors
leads to the production of IL-6 (Chapter II). Other investigators have shown that oxPAPC
stimulates IL-6 production and that PEIPC can activate downstream components of the
IL-6 signaling pathway such as Stat3 (Furnkranz et al., 2005d;Imai et al., 2008;Yeh et al.,
2004). IL-6 is required for optimal responses to oxPAPC (Furnkranz et al., 2005a;Van
Lenten et al., 2001a). Our data reveal that the long-chain fraction of oxPAPC induces IL6 expression and that this is required for optimal PAFAH expression (Figure 13).
Preliminary data reveals that Stat3 activation through tyrosine and serine phosphorylation
occurs following treatment with oxPAPC (Figure 13). The 5’ flanking regions of both IL6 and PAFAH contain canonical GAS elements that potentially bind activated Stat3.
Mice that have selective deletion of endothelial Stat3 develop smaller atherosclerotic
lesions than wild type mice (Gharavi et al., 2006). Pravastatin treated ApoE null mice
have significantly reduced atherosclerotic lesions, reduced levels of IL-6 and
phosphorylated Stat3 (Zhou et al., 2008). Expression of the adhesion protein intercellular
adhesion molecule-1 (ICAM-1) is induced following the formation of a complex between
Stat3 and Sp1 that binds a GAS element (Yang et al., 2005). The PAFAH 5’ flanking
region contains a canonical GAS sequence (TTCAGAGAA) that is located within
approximately 250 nucleotides of the GC-box (Cao et al., 1998e)(Figure 27). We
hypothesize that oxPAPC-induced activation of Stat3 leads to its association with Sp1
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thereby inducing PAFAH expression. This is a novel system for the regulation of
PAFAH. Further studies are required to investigate the role of Stat3 in oxPAPC-induced
PAFAH expression. Our studies will use pharmacological inhibitors of Stat3 as well as
the generation of modified PAFAH promoter constructs that will test whether Stat3 is a
requirement for the upregulation of PAFAH expression. Furthermore we will investigate
the potential for oxPAPC-activated Stat3 forming a complex with Sp1 to induce PAFAH
expression.

This study revealed that macrophages generated from primary monocytes in vitro express
very low levels of the IL-6 receptor (Figure 13). This, perhaps combined with their high
PAFAH expression renders them largely unresponsive to oxPAPC. Given that
macrophages are classically associated with atherosclerosis, we are particularly intrigued
that their PAFAH regulation is unaffected by oxidized phospholipids. These bioactive
lipids are important to the development of atherosclerosis and it is therefore interesting
that monocytes and DC alone respond. Macrophages express both DP1 and EP2 (Figure
11) and we predict that they are able to bind PEIPC in long-chain fractions of oxPAPC.
Macrophages may hydrolyze these oxPL too rapidly to allow them to bind these receptors
however given that they are less efficient substrates we predict that a fraction of these
oxPL persist. oxPL binding would lead to IL-6 production but the low expression of the
IL-6 receptor predicts that IL-6 does not signal in an autocrine fashion upon the
macrophage. We predict that macrophage-generated IL-6 in the atheroma would instead
bind IL-6 receptors upon the DC and reinforce the upregulation of PAFAH. This would
142

lead to a massive induction of PAFAH in the atheroma and potentially contributes to the
elevated PAFAH levels observed in atherosclerosis. This notion should be tested in future
experiments for example by stimulating macrophages with oxPAPC and incubating DC
with the conditioned media from these studies.

IL-6 is not solely generated by oxPAPC. While our observations with oxPAPC are
important to atherosclerosis, we must recognize that other factors are present in the
atheroma that could potentially elevate IL-6 levels to induce PAFAH. One factor in
particular is sphingosine 1-phosphate (S1P). The bioactive lipid S1P induces IL-6 release
from macrophages (Price et al., 2009). S1P is implicated in atherosclerosis although it is
unknown whether its role is pro- or anti-atherogenic. S1P stimulates proliferation and
migration of vascular smooth muscle cells, both are pro-atherogenic actions (Levade et
al., 2001). Additionally S1P exerts anti-apoptotic effects upon T cells and leukocytes, this
would allow persistence of these cells in the atheroma and allow them to continue to
produce inflammatory cytokines (Cuvillier et al., 1998). Conversely, HDL-associated
S1P is reported to be protective in cardiovascular disease (Sattler and Levkau, 2009).

OxPAPC has been demonstrated by other investigators to signal through several
receptors in addition to DP1/EP2 including the TLR/CD14 receptor complex (Erridge et
al., 2008;Miller et al., 2003;Miller et al., 2005;Walton et al., 2003a). LPS the classic
ligand for TLR4 induces PAFAH expression by increasing the activity of Sp1 (Wu et al.,
2003). The transcription factors Sp1 and Sp3 are required for basal PAFAH activity (Wu
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et al., 2003). oxPAPC suppresses LPS signaling in endothelial cells (Bochkov et al.,
2002). Our own preliminary experiments indicate a similar phenomenon in THP1
monocytes (Figure 26). Presently there is no definitive cause for these observations.
There is speculation that oxPAPC can interfere with the construction of the LPS/TLR4
receptor complex either by binding directly to a component of the signaling unit or by
disruption of the complex by membrane alterations (Bochkov et al., 2002;Erridge et al.,
2008). We are intrigued by our similar observations in THP1 monocytes especially
considering our findings with oxPAPC and IL-6 and the regulation of PAFAH. Other
reports have shown that IL-6 also suppresses LPS signaling in DC (Hegde et al., 2004).
This research also demonstrated suppression of the chemotactic response of
phenotypically mature DC towards CCR7, an action that would lead to the trapping of
DC in the atheroma. Importantly, IL-6 also suppressed LPS-stimulated activation of NFkB. This is particularly interesting given the lack of NF-kB signaling downstream of
oxPL. The authors concluded that DC incubated with IL-6 were phenotypically mature
but functionally impaired DC (Hegde et al., 2004). This notion that is intriguing when
one considers that DC become trapped at sites of dyslipidemia mimicking atherosclerosis
(Angeli et al., 2004c). All together these data suggest that IL-6 participates in the
oxPAPC-mediated suppression of LPS signaling.
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Figure 26: oxPAPC Suppresses LPS Signaling in THP-1 Monocytes. THP1
monocytes were treated with 100ng/ml LPS, 10µg/ml oxPAPC or both for 16 hours then
PAFAH expression was quantified by qPCR. The data represent a single experiment
conducted in triplicate. Data are expressed as mean ± standard deviation relative to
control.
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Figure 27: Depiction of the PAFAH 5’ flanking region. +1 refers to transcription start
site. The GC-box has been confirmed. The sequence of the putative GAS element is
TTCAGAGAA (-340 - -332). The proposed negative regulatory regions are inferred
from analyses of transcriptional activity in truncated constructs by other investigators.
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OxPL have also been demonstrated to induce IL-8 through the activation of Stat3
(Gharavi et al., 2006). Preliminary work conducted in our laboratory indicates that IL-8
may also regulate PAFAH expression (Figure 28). Intriguingly, IL-8 treatment of DC and
macrophages follows a similar pattern to IL-6 treatment where macrophages are largely
unresponsive (Figure 28). Further studies are warranted to investigate this intriguing
observation and to determine whether oxPAPC induces IL-8 in the monocytic cell model.
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Figure 28: IL-8 Induces PAFAH Expression. Cytokine-differentiated macrophages and
dendritic cells were treated with IL-8 at the indicated concentrations for 16 hours. Cell
free supernatants were subjected to PAFAH activity assays.
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Our data reveal that mildly oxidized preparations of LDL alone can significantly induce
PAFAH expression (Figure 14). Our method for the oxidation of LDL was originally
used by Anthonsen et al to study the regulation of sPLA2 by oxLDL (Anthonsen et al.,
2000c). They too found that mildly oxidized LDL was the strongest inducer of their
phospholipase A2 and that further oxidation led to the loss of any significant changes in
sPLA2 expression. While mild oxidation of LDL likely leads to the production of longchain oxPL, heavy oxidation continues the modification and fragmentation of the sn-2
acyl chain likely leading to the generation of short-chain, PAF-like oxPL. Other studies
have revealed that minimally oxLDL can offset the effects of extensively oxLDL
(Boullier et al., 2006). Further studies with mass spectrometry are warranted to
investigate the relative component oxPL of the species of oxLDL. It is possible that
PAFAH expression is not induced because the long-chain oxPL become fragmented but
equally as possible is that the emergence of PAF-like oxPL leads to the suppression of
the long-chain oxPL response. These observations are important when one considers the
outcome in the atheroma. Early in atherosclerosis when long-chain oxPL are abundant,
one would predict that PAFAH expression would be robustly upregulated. As more
extensive oxidation occurs, the relative level of PAFAH may decline. In agreement with
this notion, PAFAH levels are elevated in early atherosclerosis but are later almost
undetectable.

This study reveals DC to be important mediators of the response to oxPAPC. DC are
sensitive to long-chain fractions of oxPAPC unlike the unresponsive macrophages
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(Figure 10). Macrophages have long been associated with atherosclerosis however the
role of DC in atherosclerosis is an emerging field. Bobryshev identified that DC are not
only present in the atheroma but are localized to rupture-prone shoulder regions of the
plaque (Bobryshev, 2000b). DC are also thought to be involved in maturation of the
plaque and perhaps in the instability of advanced lesions (Bobryshev, 2000c). Our data
reveal that PAFAH activity is significantly upregulated in DC. Elevated DC PAFAH may
lead to the catabolism of oxPL and thus the generation of LPC. LPC induces apoptosis
and interferes with membrane integrity and could be the source of the instability at
shoulder regions of the plaque. Angeli et al showed that DC may become trapped in the
atheroma (Angeli et al., 2004c). This, together with our data strongly suggests that
oxPAPC-stimulated DC are the cause of plaque instability.

PAFAH has been the source of much controversy regarding its role in atherosclerosis.
The elevated levels of the enzyme detected in atherosclerosis are undeniable (Packard et
al., 2000b;Tselepis and Chapman, 2002a;Wilensky et al., 2008). Our study shows that
long-chain oxPL are, at least in part responsible for the induction of PAFAH observed.
PAFAH degrades pro-inflammatory oxPL. These oxPL are known to stimulate
monocyte-migration to the atheroma, induce differentiation and smooth muscle cell
proliferation and migration (Chatterjee et al., 2004;Cherepanova et al., 2009;Frostegard et
al., 1997c). The catabolism of these oxPL would therefore suppress these pro-atherogenic
activities and protect the artery from further damage. The ultimate outcome of PAFAH
however may also be damaging as the products of the reaction, LPC and oxidized free
150

fatty acids are also potent pro-inflammatory mediators. Treatment of THP1 monocytes
with POVPC leads to cell death. At this stage we do not know whether this is a direct
consequence or whether POVPC is catabolyzed and the products of the reaction are the
cell death stimulus. There are many examples of the protective effects of PAFAH in
animal models. For example increased PAFAH reduces atherosclerosis and neointimal
formation (Arakawa et al., 2005b;Quarck et al., 2001b;Turunen et al., 2005b). PAFAH is
also able to restore the migration of DC to the lymph in apoE null mice (Angeli et al.,
2004c). These examples are likely a consequence of the catabolism of oxPL. While LDLassociated PAFAH is often damaging, HDL-associated PAFAH may be protective. For
example it is HDL-associated PAFAH that restores DC migration out of the atheroma.
Conversely PAFAH is also associated with increased incidence of cardiovascular disease
(Blankenberg et al., 2003a;Stafforini et al., 1987a;Stafforini et al., 1997b) and directly
correlates with lesion severity severity (Hakkinen et al., 1999). These observations are
likely a direct consequence of the products of the PAFAH reaction. A PAFAH inhibitor,
Darapladib is currently in Phase III clinical trials. Darapladib transiently decrease
circulating C-reactive protein (CRP) and interleukin-6 (IL-6) (Mohler, III et al., 2008)
Additionally, there is a significant reduction in necrotic core progression suggesting that
PAFAH does indeed play a role in atherosclerosis development (Wilensky et al., 2008).
We are intrigued by the transient nature of the CRP and IL-6 suppression. These studies
suggest while short-term inhibition of PAFAH lowers inflammation, long-term
inflammation is restored. This suggests that over time, the suppression of PAFAH may
not be as protective. While suppression of PAFAH in the atheroma appears to have a
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protective outcome, the global suppression of PAFAH may impact the resolution of
inflammation by allowing persistently elevated levels of PAF. Furthermore, the inhibition
of PAFAH in the atheroma allows the accumulation of oxPL that signal the influx of
monocytes as well as a variety of pro-inflammatory events. We predict that while
PAFAH is a key player in the progression of the atheroma, it retains some antiatherogenic and anti-inflammatory characteristics. We predict that the long-term
inhibition of this enzyme may impact inflammation in general.
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Regulation of PAFAH Expression by Oxidized Phospholipids
Griffiths R.
Virginia Commonwealth University, Richmond, Virginia

2008

Arteriosclerosis Thrombosis & Vascular Biology 9th Annual
Conference
Regulation of PAFAH by Oxidized Phospholipids. Abstract P303.
Griffiths R, Leitinger N and Barbour S.E.
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2007

South Eastern Regional Lipid Conference
Regulation of PAFAH Expression by Oxidized Lipids
Griffiths R, Leitinger N. and Barbour S.E.
Cashiers, North Carolina

2007

Integrated Cell and Molecular Signaling Research Retreat
Regulation of PAFAH by Oxidized Phospholipids
Griffiths R, Leitinger N and Barbour S.E.

2007

24th Annual Daniel T Watts Research Poster Symposium
Regulation of PAFAH by Oxidized Phospholipids
Griffiths R, Leitinger N. and Barbour S.E.

2007

35th Annual John C Forbes Research Colloquium
Regulation of PAFAH Expression by Oxidized Lipids
Griffiths R, Leitinger N. and Barbour S.E.
Virginia Commonwealth University, Richmond, Virginia

2007

American Society of Biochemistry and Molecular Biology Conference
Regulation of PAF Acetylhydrolase Expression by Bioactive Lipids.
Abstract 779.9.
Griffiths R, Lin J, Leitinger N, van Antwerpen R, Tew J.G, Schenkein
H.A. and Barbour S.E.

2007

Keystone Symposium on Bioactive Lipids
Platelet-Activating Factor Acetylhydrolase in Aggressive Periodontitis
and Cardiovascular Disease
Barbour, S.E., Griffiths, R., Lin, J. Leitinger, N., van Antwerpen, R.,
Tew, J.G, and Schenkein, H.A.
Taos, New Mexico
192

2006

South Eastern Regional Lipid Conference
Regulation of PAFAH Expression by PAF and Oxidized Lipids
Griffiths R, Lin J, van Antwerpen R, Schenkein H.A, Tew J.G. and
Barbour S.E.
Cashiers, North Carolina

2006

Signaling and Metabolism of Bioactive Lipids Seminar Series
Regulation of PAFAH by PAF and Oxidized Low Density Lipoprotein
Griffiths R.
Virginia Commonwealth University, Richmond, Virginia

2006

Integrated Cell and Molecular Signaling Seminar Series
Regulation of PAFAH by PAF and Oxidized Phospholipids
Griffiths R, Lin J, van Antwerpen R, Schenkein H.A, Tew J.G and
Barbour S.E.
Virginia Commonwealth University, Richmond, Virginia

2006

23rd Annual Daniel T. Watts Research Poster Symposium
Regulation of PAFAH by PAF and Oxidized Phospholipids
Griffiths R, Lin J, van Antwerpen R, Schenkein H.A, Tew J.G. and
Barbour S.E.

2006

34th Annual John C Forbes Research Colloquium
Monocyte Differentiation and PAFAH Expression in Periodontitis
Griffiths R, van Antwerpen R, Schenkein H.A, Tew J.G. and
Barbour S.E
Virginia Commonwealth University, Richmond, Virginia
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2006

Arteriosclerosis Thrombosis and Vascular Biology 7th Annual
Conference
Regulation of Lipoprotein Associated Phospholipase A2 by Platelet
Activating Factor and Oxidized Low Density Lipoprotein. Poster #148
Griffiths R, Lin J, van Antwerpen R, Schenkein H.A, Tew J.G and
Barbour S.E.

2005

South-Eastern Regional Lipid Conference
Regulation of PAFAH Expression by PAF and Oxidized LDL
Griffiths R, Shin C.R, Lin J, van Antwerpen R, Tew J.G, Schenkein H.A
and Barbour S.E.

2005

Integrated Cell and Molecular Signaling Research Retreat
Regulation of PAFAH Expression by PAF and Oxidized LDL
Griffiths R, Lin J, van Antwerpen R, Tew J.G, Schenkein H.A. and
Barbour S.E.

2005

22nd Annual Daniel T. Watts Research Poster Symposium
Regulation of PAFAH Expression by PAF and Oxidized LDL
Griffiths R¸ Shin C.R, Lin J, van Antwerpen R, Tew J.G, Schenkein
H.A. and Barbour S.E.

2004

Signaling and Metabolism of Bioactive Lipids Research Retreat
PAF and Oxidized Lipids in Periodontitis and Atherosclerosis
Griffiths R, Shin C.R, Lin J, van Antwerpen R, Tew J.G, Schenkein H.A.
and Barbour S.E.
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2004

20th Daniel T. Watts Research Poster Symposium
I. Regulation of PAFAH by Oxidized LDL
Griffiths R, van Antwerpen R. and Barbour S.E.
II. oxLDL Induced Release of Arachidonic Acid Release by
RAW264.7 and J774.1 Macrophages May be Mediated by
Ceramide-1-Phosphate
Griffiths R, Chalfant C.E, Barbour S.E. and
van Antwerpen R.
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